CN118027058A - 15-PGDH inhibitors - Google Patents

15-PGDH inhibitors Download PDF

Info

Publication number
CN118027058A
CN118027058A CN202311513322.1A CN202311513322A CN118027058A CN 118027058 A CN118027058 A CN 118027058A CN 202311513322 A CN202311513322 A CN 202311513322A CN 118027058 A CN118027058 A CN 118027058A
Authority
CN
China
Prior art keywords
alkyl
alkylene
pharmaceutically acceptable
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311513322.1A
Other languages
Chinese (zh)
Inventor
张学军
臧杨
李群
汤亚敏
王猛
丁肖华
李莉娥
杨俊�
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humanwell Healthcare Group Co ltd
Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co
Original Assignee
Humanwell Healthcare Group Co ltd
Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanwell Healthcare Group Co ltd, Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co filed Critical Humanwell Healthcare Group Co ltd
Publication of CN118027058A publication Critical patent/CN118027058A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a heterocyclic compound shown in a formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of the pharmaceutically acceptable salt thereof or a prodrug thereof; the compound has better 15-PGDH inhibition effect.

Description

15-PGDH inhibitors
Technical Field
The invention belongs to the field of medicines, and particularly relates to a 15-PGDH inhibitor.
Background
The 15-hydroxyprostadil dehydrogenase (15-PGDH) gene is located on chromosome 4, namely 4q 34-q 35, with a span of about 31kb, and has 7 exons in total and a molecular weight of 29kD.15-PGDH consists of 266 amino acids, belongs to the family of short-chain dehydrogenases (SDR-chain dehydrogenases), and consists of two identical subunits forming a dimer, but it is also considered that it is enzymatically active in the presence of monomers. 15-PGDH is a key enzyme for degradation and inactivation of Prostaglandins (PGs) and related eicosanoids, and is widely found in normal tissues such as the lung, kidney, gastrointestinal tract, thyroid gland, prostate gland and placenta of humans and mammals, and can catalyze the oxidation of active 15-hydroxy Prostaglandins to 15-keto Prostaglandins with greatly reduced activity on the one hand, and degrade polycyclic aromatic hydrocarbons other than Prostaglandins in the presence of NAD + coenzyme factors, and reduce the generation of carcinogens and pro-carcinogens under physiological or pathological conditions through oxidation reactions.
No 15-PGDH inhibition pathway is currently marketed for the treatment of a number of conditions including fibrosis. Thus, the development of novel compounds that inhibit 15-PGDH activity would be of positive interest for the treatment of diseases.
Disclosure of Invention
It is an object of the present invention to provide a novel compound useful as a 15-PGDH inhibitor.
In a first aspect of the invention, there is provided a heterocyclic compound, solvate, pharmaceutically acceptable salt, solvate of a pharmaceutically acceptable salt or a prodrug of a pharmaceutically acceptable salt of formula I:
Wherein,
Ring a is a C 3-C20 alicyclic hydrocarbon group;
R a is H, halogen, hydroxy, amino, nitro, cyano, carbonyl, oxo, carboxy, C 1-C6 alkyl, -NH (C 1-C6 alkyl), C 1-C6 deuterated alkyl, C 2-C6 alkynyl, halogenated C 1-C6 alkyl, hydroxyC 1-C6 alkyl, C 1-C6 alkylcarbonyl, C 1-C6 alkoxy or halogenated C 1-C6 alkoxy; when R a is a plurality of substituents, the substituents are the same or different;
r 1 is C 1-C6 alkyl, C 1-C6 deuterated alkyl, halogenated C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), C 1-C6 alkoxy, - (C 1-C6 alkylene) - (C 1-C6 alkoxy), 3-11 membered heterocycloalkyl, or- (C 1-C6 alkylene) - (3-11 membered heterocycloalkyl); and, the R 1 is optionally substituted with one or more R 1-1; when there are a plurality of substituents, the substituents may be the same or different;
R 1-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, C 1-C6 alkyl, C 1-C6 deuterated alkyl, halogenated C 1-C6 alkyl, C 1-C6 alkoxy or deuterated C 1-C6 alkoxy;
R 2 is amino, CN or-NHC (O) alkyl;
R 3 is aryl, 3-11 membered heterocycloalkyl, or 3-11 membered heteroaryl, optionally substituted with one or more R 3-1; when there are a plurality of substituents, the substituents may be the same or different; the heteroatom is selected from one or more of N, O, S;
R 3-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-N (R 3-1-1)2、-N(R3-1-1)2、-N(R3-1-1) (alkylene-OH), -N (R 3-1-1) (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halo C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C8 cycloalkyl, 3-11 membered heterocycloalkyl, -C (O) N (R 3-1-1)2、-C(O)N(R3-1-1) (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halo C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) p-C1-C6 alkyl, or-S (=O) (= NR 3-1-1)-R3 -1-1, wherein the C 3-C8 cycloalkyl and the 3-11 membered heterocycloalkyl are each optionally substituted by R 3-1-2;
Each R 3-1-1 is independently H, C 1-C6 alkyl or alkylene-OH, optionally substituted with: -OH, -alkylene-NH 2, -alkylene-N (R 3-1-3) 2, -alkylene-O-alkylene-OH, -alkylene-O-alkylene-NH 2, -C (O) -alkyl, -C (O) O-alkyl, -alkylene-COOH or-S (O) p -alkyl; or alternatively, in-O-alkylene-N (R 3-1-1)2 or-N (R 3 -1-1)2, two R 3-1-1 together with the N atom to which they are attached form a 4-7 membered heterocyclic ring, optionally containing a further heteroatom selected from O, S, or N, and wherein the 4-7 membered heterocyclic ring is optionally substituted with R 3-1-4; or alternatively, in-S (=o) (=nr 3-1-1)-R3-1-1, two R 3-1-1 together with the N and S atoms to which they are attached form a 4-7 membered heterocyclic ring);
R 3-1-2 is hydroxy, halogen, C 1-C6 alkyl or C 1-C6 alkoxy;
R 3-1-3 is H or C 1-C6 alkyl, or two R 3-1-3 together with the N atom to which they are attached may form a 4-7 membered heterocyclic ring, the 4-7 membered heterocyclic ring optionally containing a further heteroatom selected from O, S (O) r or N;
r 3-1-4 is halogen, C 1-C6 alkyl or C 1-C6 alkoxy;
m, n, p, r is 0, 1 or 2, respectively.
In the present invention, the definition of some substituents in the heterocyclic compounds shown in the formula I can be as follows, and the definitions of the substituents which are not mentioned are as described in any scheme.
In a preferred embodiment of the invention, R 1 is C 1-C6 alkyl, C 1-C6 deuterated alkyl, halogenated C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), C 1-C6 alkoxy, - (C 1-C6 alkylene) - (C 1-C6 alkoxy), 3-11 membered heterocycloalkyl, or- (C 1-C6 alkylene) - (3-11 membered heterocycloalkyl); and, the R 1 is optionally substituted with one or more R 1 -1; when there are a plurality of substituents, the substituents may be the same or different; the hetero atoms of the heterocyclic alkyl are selected from one or more of N, O, S, and the number of the hetero atoms is 1,2 or 3.
In a preferred embodiment of the invention, R 1-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, C 1-C6 alkyl, C 1-C6 deuterated alkyl, halogenated C 1-C6 alkyl, C 1-C6 alkoxy or deuterated C 1-C6 alkoxy; the alkylene is a C 1-C6 alkylene.
In a preferred embodiment of the invention, R 2 is amino, CN or-NHC (O) alkyl; the alkyl is C 1-C6 alkyl.
In a preferred embodiment of the invention, R 3 is aryl, 3-11 membered heterocycloalkyl, or 3-11 membered heteroaryl, optionally substituted with one or more R 3-1; when there are a plurality of substituents, the substituents may be the same or different; the hetero atoms in the heterocycloalkyl and heteroaryl are selected from one or more of N, O, S, and the number of the hetero atoms is 1, 2 or 3; the aryl is 6-10 membered aryl.
In a preferred embodiment of the invention, R 3-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-N (R 3-1-1)2、-N(R3-1-1)2、-N(R3-1-1) (alkylene-OH), -N (R 3-1-1) (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halo C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C8 cycloalkyl, 3-11 membered heterocycloalkyl, -C (O) N (R 3-1-1)2、-C(O)N(R3-1-1) (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halo C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) p-C1-C6 alkyl or-S (=o) (=nr 3-1-1)-R3-1-1), wherein each of said C 3-C8 cycloalkyl and said 3-11 membered heterocycloalkyl is optionally substituted by R 3 -1-2, said alkylene is C 1-C6 alkylene, said alkyl is a heteroatom selected from the group consisting of 3-to one or more of the heteroatoms selected from the group consisting of 5326, and 3-membered heteroatom.
In a preferred embodiment of the invention, each R 3-1-1 is independently H, C 1-C6 alkyl or alkylene-OH, optionally substituted with: -OH, -alkylene-NH 2, -alkylene-N (R 3-1-3) 2, -alkylene-O-alkylene-OH, -alkylene-O-alkylene-NH 2, -C (O) -alkyl, -C (O) O-alkyl, -alkylene-COOH or-S (O) p -alkyl; or alternatively in-O-alkylene-N (R 3-1-1)2 or-N (R 3-1-1)2, two R 3-1-1 together with the N atom to which they are attached form a 4-7 membered heterocyclic ring containing N and optionally a heteroatom containing O or S, and wherein the 4-7 membered heterocyclic ring is optionally substituted with R 3-1-4; or alternatively in-S (=o) (=nr 3-1-1)-R3-1-1, two R 3-1-1 together with the N and S atoms to which they are attached form a 4-7 membered heterocyclic ring; the alkylene is C 1-C6 alkylene; the alkyl is C 1-C6 alkyl).
In a preferred embodiment of the invention, R 3-1-3 is H or C 1-C6 alkyl, or both R 3-1-3 together with the N atom to which they are attached can form a 4-7 membered heterocyclic ring containing N and optionally a heteroatom containing O or S (O) r.
In a preferred embodiment of the invention, the ring A is a C 3-C12 alicyclic hydrocarbon group, preferably, the ring A is a C 3-C7 alicyclic hydrocarbon group.
In a preferred embodiment of the invention, the ring A is cyclopentyl, cyclohexyl, bicyclo [3.1.0] hexyl or spiro [2.4] heptane.
In a preferred embodiment of the invention, R a is methyl.
In a preferred embodiment of the invention, R 1 is C 1-C4 alkyl, C 1-C4 deuterated alkyl, halogenated C 1-C4 alkyl, C 3-C6 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C6 cycloalkyl), C 1-C4 alkoxy, - (C 1-C4 alkylene) - (C 1-C4 alkoxy), 3-6 membered heterocycloalkyl, or- (C 1-C4 alkylene) - (3-6 membered heterocycloalkyl); and, the R 1 is optionally substituted with one or more R 1-1; the definition of R 1-1 is as described in the first aspect of the invention.
In a preferred embodiment of the invention, R 1 is butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, - (CH 2)x -cyclopropyl, - (CH 2) x -cyclobutyl, - (CH 2)x -cyclopentyl, - (CH 2) x -cyclohexyl or- (C 1-C4 alkylene) - (C 1-C4 alkoxy), wherein x is 1, 2 or 3.
In a preferred embodiment of the invention, R 1-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C3 alkyl), -O-alkylene-OH, C 1-C3 alkyl, deuterated C 1-C6 alkyl, halogenated C 1-C3 alkyl, C 1-C3 alkoxy, deuterated C 1-C3 alkoxy.
In a preferred embodiment of the invention, R 2 is-NH 2, CN or-NH-C (O) -CH 3.
In a preferred embodiment of the invention, said R 3 is a 5-6 membered heterocycloalkyl or 5-10 membered heteroaryl, optionally substituted with one or more R 3-1, said R 3-1 being as defined in the first aspect of the invention.
In a preferred embodiment of the invention, R 3 is a 5-6 membered heteroaryl optionally substituted with one or more R 3-1, or is an 8-10 membered bicyclic heteroaryl optionally substituted with one or more R 3-1, the definition of R 3-1 being as described in the first aspect of the invention.
In a preferred embodiment of the invention, R 3-1 is H, methyl, oxo, -NHCH 3, or-S (=o) (=nch 3)-CH3.
As will be appreciated by those skilled in the art, in accordance with the conventions used in the art, in the structural formulae of the present application,For depicting chemical bonds, which are points where a moiety or substituent is attached to a core structure or a backbone structure.
In a second aspect of the present invention, there is provided a compound of formula I-1, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof:
Wherein X 1、X2、X3、X4 and X 5 each independently represent a ring atom; x 1、X2、X3、X4 and X 5 are each independently N, O, S, CH 2, CH or C; the bond connected between X 4、X5 is a single bond or a double bond; b is absent or B forms together with the X 4、X5 ring atom a 3-7 membered heterocycloalkyl, 5 membered heteroaryl or 6 membered heteroaryl ring; the heteroatom is selected from one or more of N, O, S; r b、Rc is each independently H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-N (R 3-1-1)2、-N(R3-1-1)2、-N(R3-1-1) (alkylene-OH), -N (R 3-1-1) (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halo C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C8 cycloalkyl, 3-11 membered heterocycloalkyl, -C (O) N (R 3-1-1)2、-C(O)N(R3 -1-1) (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halo C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) p-C1-C6 alkyl, or-S (=O) (=NR 3-1-1)-R3-1-1; when said R b or R c is a plurality of substituents, said substituents are the same or different, S, t are each 0, 1 or 2;R 1、R2、R3-1-1、Ra, p and m as defined herein.
In a preferred embodiment of the invention, B is absent or B forms together with the X 4、X5 ring atom a 3-7 membered heterocycloalkyl, 5 membered heteroaryl or 6 membered heteroaryl ring; the heteroatoms in the heterocycloalkyl and heteroaryl groups are selected from one or more of N, O, S.
In a preferred embodiment of the invention, the alkylene is a C 1-C6 alkylene.
In a preferred embodiment of the invention, theSelected from 6 membered heteroaryl groups containing 1 or more heteroatoms, 6 membered heteroaryl and 3-7 membered heterocycloalkyl, 6 membered heteroaryl and 5-6 membered heteroaryl; the heteroatom is selected from N, O or S.
In a preferred embodiment of the invention, theSelected from the group consisting of pyridine, pyrimidine, pyridazine, pyridocyclobutyl, pyridocyclopentyl, pyridoimidazole, pyridopyrazole, pyridofuran, pyridopyrimidine, pyridothiophene, pyridothiazole.
In a preferred embodiment of the invention, theSelected from pyridine, pyrimidine, pyridopyrazole.
In a preferred embodiment of the invention, theSelected from pyridine, pyrimidine,/>
In a preferred embodiment of the invention, each R b、Rc is independently H, halogen, hydroxy, amino, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-NH 2, -NH (alkylene-OH), -NH (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halo C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C6 cycloalkyl, 3-7 membered heterocycloalkyl, -C (O) NH 2, -C (O) NH (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halo C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) 2-C1-C6 alkyl or-S (=o) (=nch 3)-C1-C6 alkyl), preferably, the alkylene is C 1-C6 alkylene.
In a preferred embodiment of the invention, each R b、Rc is independently H, oxo, C 1-C4 alkyl, -NH (C 1-C4 alkyl), C 1-C4 deuterated alkyl, C 2-C4 alkynyl, halogenated C 1-C4 alkyl, hydroxyC 1-C4 alkyl, C 1-C4 alkoxy, halogenated C 1-C4 alkoxy.
In a preferred embodiment of the invention, each R b、Rc is independently H, oxo, methyl, -NHCH 3、-S(＝O)(＝NCH3)-CH3.
In a third aspect of the present invention, there is provided a compound of formula I-2, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof:
Wherein X 1、X2、X3 and X 4 each independently represent a ring atom; x 1、X2、X3 and X 4 are each independently N, O, S, CH 2, CH or C; r b is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-N (R 3-1-1)2、-N(R3-1-1)2、-N(R3-1-1) (alkylene-OH), -N (R 3-1-1) (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halo C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C8 cycloalkyl, 3-11 membered heterocycloalkyl, -C (O) N (R 3-1-1)2、-C(O)N(R3-1-1) (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halo C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) p-C1-C6 alkyl, or-S (=O) (=NR 3-1-1)-R3-1-1; when said R b is a plurality of substituents, said substituents are the same or different; S is 0, 1 or 2;R 1、R2、R3-1-1、Ra, p and m are as defined in the first aspect of the invention.
In a preferred embodiment of the invention, the alkylene is a C 1-C6 alkylene.
In a preferred embodiment of the invention, theFor/>
In a preferred embodiment of the invention, the halogen is F, cl, brr or I.
In a preferred embodiment of the invention, the alkyl is a C 1-C6 alkyl, preferably a C 1-C4 alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
In a preferred embodiment of the invention, the C 1-C6 haloalkyl is-CvFw, wherein v=1 to 3,w =1 to (2v+1), such as trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2-trifluoroethyl, heptafluoropropyl or heptachloropropyl.
In a preferred embodiment of the invention, the C 3-C8 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
In a preferred embodiment of the invention, the alkylene is a C 1-C6 alkylene, preferably a C 1-C4 alkylene, such as methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, sec-butylene or tert-butylene.
In a preferred embodiment of the invention, the C 1-C6 alkoxy group is a C 1-C4 alkoxy group, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
In a preferred embodiment of the present invention, the 3-11 membered heterocycloalkyl is a 5-6 membered heterocycloalkyl.
In a preferred embodiment of the present invention, the heteroatom of the 3-11 membered heterocycloalkyl is selected from one or more of N, O, S; the number of heteroatoms is 1, 2 or 3.
In a preferred embodiment of the invention, the aryl group in R 3 is a 6-10 membered aryl group, such as phenyl or naphthyl.
In a preferred embodiment of the invention, said heteroatom in R 3 is a heteroatom in said 3-11 membered heterocycloalkyl or 3-11 membered heteroaryl.
In a preferred embodiment of the present invention, the 4-7 membered heterocycle is a 4-7 membered heterocycloalkyl.
In a preferred embodiment of the present invention, the heteroatom of the 4-7 membered heterocyclic ring is selected from one or more of N, O, S; the number of heteroatoms is 1, 2 or 3.
In a preferred embodiment of the present invention, the heterocyclic compound of formula I has a structure of formula I-3:
Wherein R 1、R3、Ra, m are as defined in the first aspect of the invention.
In a preferred embodiment of the present invention, the heterocyclic compound of formula I has the structure of formula I-4:
Wherein R 1、R3、Ra, m are as defined in the first aspect of the invention.
In a preferred embodiment of the present invention, the heterocyclic compound of formula I has the structure of formula I-5:
Wherein R 1、R3、Ra, m are as defined in the first aspect of the invention.
In a preferred embodiment of the present invention, the heterocyclic compound of formula I has the structure of formula I-6:
Wherein R 1、R3、Ra, m are as defined in the first aspect of the invention.
In a preferred embodiment of the invention, ring A is C 3-C7 cycloalkyl.
In a preferred embodiment of the invention, R a is C 1-C6 alkyl.
In a preferred embodiment of the invention, R 1 is C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), C 1-C4 alkoxy, - (C 1-C6 alkylene) - (C 1-C6 alkoxy); and, the R 1 is optionally substituted with one or more R 1-1; when there are a plurality of substituents, the substituents may be the same or different;
Preferably, R 1 is C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), - (C 1-C6 alkylene) - (C 1-C6 alkoxy).
In a preferred embodiment of the invention, R 2 is amino.
In a preferred embodiment of the invention, R 3 is a 3-11 membered heterocycloalkyl or 3-11 membered heteroaryl, optionally substituted with one or more R 3-1; when there are a plurality of substituents, the substituents may be the same or different; the heteroatom in the 3-11 membered heterocycloalkyl or 3-11 membered heteroaryl is selected from one or more of N, O, S; the number of heteroatoms is 1,2 or 3.
In a preferred embodiment of the invention, each R 3-1 is independently C 1-C6 alkyl, oxo, -NH (C 1-C6 alkyl), or-S (=o) (=nr 3-1-1)-R3-1-1.
In a preferred embodiment of the invention, each R 3-1-1 is independently H, C 1-C6 alkyl or C 1-C6 alkylene-OH.
In a preferred embodiment of the invention, R 1 is
In a preferred embodiment of the invention, R 3 is Each of which is optionally substituted with one or more of R 3-1 described above.
In a preferred embodiment of the invention, R 3 is
In a preferred embodiment of the present invention, the heterocyclic compound of formula I is a heterocyclic compound of formula I-7,
Wherein ring A is a C 3-C7 alicyclic hydrocarbon group;
Each R a is independently C 1-C6 alkyl;
m is 0,1 or 2;
R 1 is C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), C 1-C6 alkoxy or- (C 1-C6 alkylene) - (C 1-C6 alkoxy);
R 2 is amino, CN or-NH-C (O) -CH 3;
R 3 is a 5-6 membered heterocycloalkyl or 5-10 membered heteroaryl, optionally substituted with one or more R 3-1; the heteroatoms of the heterocycloalkyl and heteroaryl groups are selected from one or more of N, O, S; the number of the hetero atoms is 1, 2 or 3;
Each R 3-1 is independently hydroxy, oxo, C 1-C6 alkyl, -NH (C 1-C6 alkyl), or-S (=o) (=nr 3-1-1)-R3 -1-1;
Each R 3-1-1 is independently C 1-C6 alkyl.
In a preferred embodiment of the present invention, the heterocyclic compound of formula I is a heterocyclic compound of formula I-8,
Wherein ring a is C 3-C7 cycloalkyl;
Each R a is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
m is 0,1 or 2;
R 1 is C 1-C4 alkyl, C 3-C6 cycloalkyl, - (C 1-C4 alkylene) - (C 3-C6 cycloalkyl) or- (C 1-C4 alkylene) - (C 1-C4 alkoxy);
r 3 is a 5-6 membered heteroaryl optionally substituted with one or more R 3-1, or is an 8-10 membered bicyclic heteroaryl optionally substituted with one or more R 3 -1; the heteroatoms of the heteroaryl group are selected from one or more of N, O, S; the number of the hetero atoms is 1, 2 or 3;
Each R 3-1 is independently oxo, C 1-C6 alkyl, -NH (C 1-C6 alkyl), or-S (=o) (=nr 3-1-1)-R3-1-1;
Each R 3-1-1 is independently C 1-C6 alkyl.
In a preferred embodiment of the present invention, the heterocyclic compound of formula I is a heterocyclic compound of formula I-9,
Wherein, the ring A is cyclopentyl, cyclohexyl, bicyclo [3.1.0] hexyl or spiro [2.4] heptane;
Each R a is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
m is 0,1 or 2;
R 1 is C 1-C4 alkyl, C 3-C6 cycloalkyl, - (C 1-C4 alkylene) - (C 3-C6 cycloalkyl) or- (C 1-C4 alkylene) - (C 1-C4 alkoxy);
R 3 is a 5-6 membered heteroaryl optionally substituted with one or more R 3-1, or is an 8-10 membered bicyclic heteroaryl optionally substituted with one or more R 3 -1; the hetero atom of the 5-6 membered heteroaryl is N, and the number of the hetero atom is 1 or 2; the hetero atom of the 8-10 membered bicyclic heteroaryl is N, and the number of the hetero atom is 1,2 or 3;
Each R 3-1 is independently oxo or C 1-C6 alkyl.
In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from any one of the following compounds:
in one aspect of the present invention, there is provided a compound of formula II,
Wherein R a、R1、R3, n and m are as defined in the first aspect of the invention;
for example:
In a fourth aspect of the present invention, there is provided a pharmaceutical composition comprising: a compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof as described in the first, second, or third aspects of the invention; and a pharmaceutically acceptable carrier.
In a fifth aspect, the present invention provides a use of a heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, a prodrug thereof or a pharmaceutical composition according to the fourth aspect of the present invention according to any one of the first, second or third aspects of the present invention; the application is to prepare a 15-PGDH inhibitor or prepare a medicament for preventing and/or treating diseases related to 15-PGDH.
Preferably, the 15-PGDH-associated disease includes, but is not limited to: fibrosis disease, inflammatory disease, cardiovascular disease, trauma, autoimmune disease, graft versus host disease, hair growth, osteoporosis, ear disease, eye disease, neutropenia, diabetes, bladder hypoactivity, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and neuronal cell death, blood cell remodeling, tissue damage, cervical disease, and kidney disease.
Preferably, the 15-PGDH-associated disease includes, but is not limited to: fibrosis disease, inflammatory disease, cardiovascular disease, trauma, autoimmune disease, graft versus host disease, hair growth, osteoporosis, ear disease, eye disease, neutropenia, diabetes, bladder hypoactivity, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and neuronal cell death, blood cell remodeling, tissue damage, cervical disease, and kidney disease. Preferably, the 15-PGDH-associated disease includes, but is not limited to: fibrotic diseases (e.g., pulmonary fibrosis, including idiopathic pulmonary fibrosis, etc., liver fibrosis, kidney fibrosis, myocardial fibrosis, scleroderma and myelofibrosis), inflammatory diseases [ such as Chronic Obstructive Pulmonary Disease (COPD), acute lung injury, sepsis, exacerbation of asthma and lung disease, inflammatory Bowel Disease (IBD) (such as ulcerative colitis and crohn's disease), peptic ulcers (such as NSAID-induced ulcers), autoimmune diseases (such as behcet's disease), vasculitis syndrome, acute liver injury, acute kidney injury, nonalcoholic fatty liver (NASH), atopic dermatitis, psoriasis, interstitial cystitis, prostatitis syndromes (such as chronic prostatitis/chronic pelvic pain syndrome) ]), cardiovascular diseases (such as pulmonary hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease, cerebral stroke and peripheral circulatory disorders), kidney diseases (such as chronic kidney disease and renal failure), wounds (such as diabetic ulcers, burns, pressure ulcers, acute mucosal injuries, including sjohne's syndrome, mucosal injuries (such as mucositis or stomatitis), injuries related to anticancer chemotherapeutics (such as DNA alkylating agents, DNA synthesised drugs, gyrase inhibitors or anti-inflammatory growth inhibitors), diseases (such as bone graft-versus-host cell-disease), autoimmune diseases (such as autoimmune diseases, radiation-induced diseases, autoimmune diseases or autoimmune diseases, such as atherosclerosis, autoimmune diseases or autoimmune diseases (such as autoimmune diseases) or host cell-induced diseases Tinnitus, dizziness and imbalance), ocular disorders (e.g., glaucoma and dry eye), neutropenia, diabetes, bladder hypoactivity, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and neuronal cell death (e.g., psychotic disorders, neurological disorders, neurotoxic disorders, neuropathic pain and neurodegenerative disorders), liver regeneration, muscle regeneration (e.g., muscle atrophy, muscular dystrophy and muscle damage), and cervical disorders.
Preferably, the tissue injury is liver injury and/or muscle injury (e.g., muscle atrophy and muscular dystrophy).
Preferably, the 15-PGDH-associated disease includes, but is not limited to: idiopathic Pulmonary Fibrosis (IPF).
Preferably, the 15-PGDH-associated disease includes, but is not limited to: liver injury.
Preferably, the 15-PGDH-associated disease includes, but is not limited to: IBD.
Preferably, the prevention and/or treatment of 15-PGDH-related diseases includes, but is not limited to: liver regeneration.
In a sixth aspect of the present invention, there is provided a use of a compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof, for the preparation of a medicament for the prevention and/or treatment of the following diseases; the disease is one or more of fibrosis disease, inflammatory disease or tissue injury.
The fibrotic disease, the inflammatory disease and the tissue damage may be as described above.
In a seventh aspect of the invention, there is provided a method of inhibiting 15-PGDH, or preventing and/or treating a disease associated with 15-PGDH, comprising the steps of: administering to a subject in need thereof a compound of formula I according to the first aspect of the invention, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof.
The 15-PGDH-related diseases are as described above.
In an eighth aspect of the invention there is provided a method of preventing or treating a disease comprising the steps of: administering to a subject in need thereof a compound of formula I according to the first aspect of the invention, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof; the disease is fibrosis disease and/or inflammatory disease.
Both the fibrotic disease and the inflammatory disease may be as described above.
In a ninth aspect of the invention, there is provided a substance X for the treatment of a 15-PGDH-related disease; the substance X is a compound shown in a formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of the pharmaceutically acceptable salt thereof or a prodrug thereof.
The 15-PGDH-related diseases are as described above.
In a ninth aspect of the invention, there is provided a substance X for the treatment of a disease; the substance X is a compound shown in a formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of the pharmaceutically acceptable salt thereof or a prodrug thereof; the disease is fibrosis disease and/or inflammatory disease.
Both the fibrotic disease and the inflammatory disease may be as described above.
Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Terminology and definitions
Unless otherwise indicated, the radical and term definitions recited in the specification and claims of the present application, including as examples, exemplary definitions, preferred definitions, definitions recited in tables, definitions of specific compounds in the examples, and the like, may be arbitrarily combined and coupled with each other. Such combinations and combinations of radical definitions and structures of compounds should fall within the scope of the present description.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. All patents, patent applications, and publications cited herein are hereby incorporated by reference in their entirety unless otherwise indicated. If there are multiple definitions of terms herein, the definitions of this chapter shall control.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the inventive subject matter. In the present application, the singular is used to include the plural unless specifically stated otherwise. It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that the use of "or" means "and/or" unless stated otherwise. Furthermore, the terms "include," as well as other forms, such as "comprising," "including," and "containing," are not limiting.
The definition of standard chemical terms can be found in references including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4THED," vols. A (2000) and B (2001), plenum Press, new York. Conventional methods within the skill of the art, such as mass spectrometry, NMR, IR and UV/VIS spectroscopy, and pharmacological methods are employed unless otherwise indicated. Unless specifically defined otherwise, the terms used herein in the description of analytical chemistry, organic synthetic chemistry, and pharmaceutical chemistry are known in the art. Standard techniques may be used in chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and treatment of patients. For example, the reaction and purification can be carried out using the manufacturer's instructions for the kit, or in a manner well known in the art or in accordance with the teachings of the present invention. The techniques and methods described above may generally be practiced according to conventional methods well known in the art, based on a number of general and more specific descriptions in the literature cited and discussed in this specification. In this specification, groups and substituents thereof can be selected by one skilled in the art to provide stable moieties and compounds.
When substituents are described by conventional formulas written from left to right, the substituents also include chemically equivalent substituents obtained when writing formulas from right to left. For example, CH 2 O is equivalent to OCH 2. As used herein,Representing the attachment site of the group. As used herein, "R 1," "R1," and "R 1" are synonymous and interchangeable. For other symbols such as R 2, the meaning of like definition is the same.
The section headings used herein are for purposes of organizing articles only and should not be construed as limiting the subject matter. All documents or portions of documents cited in this disclosure, including but not limited to patents, patent applications, articles, books, operating manuals, and treatises, are hereby incorporated by reference in their entirety.
In addition to the foregoing, when used in the specification and claims of the present application, the following terms have the meanings indicated below, unless otherwise specified.
Where a range of values recited in the specification and claims is understood to be an "integer," it is understood that both ends of the range and each integer within the range are recited. For example, an "integer of 1 to 6" should be understood to describe each integer of 0, 1, 2, 3,4, 5, and 6. When a numerical range is understood as a "number," it is understood that both endpoints of the range are noted, as well as each integer within the range, and each fraction within the range. For example, a "number of 1 to 10" should be understood to describe not only each integer of 1, 2, 3,4, 5, 6, 7, 8, 9 and 10, but also at least the sum of each integer with 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, respectively.
The term "plurality" may mean, for example, 2, 3,4, 5, 6, 7, 8, 9, 10 or more.
The term "C 3-C20 alicyclic hydrocarbon group", alone or as part of another substituent, refers to a cyclic hydrocarbon group having aliphatic character, containing a closed carbocyclic ring in the molecule, which may represent a saturated or partially unsaturated monovalent monocyclic, bicyclic or polycyclic hydrocarbon ring, also including bridged or spiro rings, for example when the alicyclic hydrocarbon group contains two or more carbocyclic rings, which may be attached in a variety of ways: the two rings in the molecule may share a single carbon atom, such a system being known as a spiro ring; the two carbon atoms on the ring can be connected by a carbon bridge to form a double-ring or multi-ring system, which is called a bridged ring; several rings may also be interconnected to form a cage-like structure. The alicyclic hydrocarbon group may have 3 to 20 carbon atoms, preferably "C 3-C12 alicyclic hydrocarbon group", and may also be "C 3-C7 alicyclic hydrocarbon group", which may have 3,4,5, 6, 7, 8, 9,10, 11, 12,13, 14, 15, 16, 17, 18, 19,20 carbon atoms. The alicyclic hydrocarbon group may be "cycloalkyl", "cycloalkenyl", "cycloalkynyl", etc. (the carbon number may be selected from any one of integers of 3 to 20 as described above), and the alicyclic hydrocarbon group may be a monocyclic hydrocarbon group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or a bicyclic hydrocarbon group such as decalin ring. For example, the term "C 3-C7 cycloalkyl" is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring, which may be a spiro or bridged ring, having 3,4,5, 6 or 7 carbon atoms. The C 3-C7 cycloalkyl group can be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [1.1.0] butyl, spiropentyl, spiro [2.3] hexyl, bicyclo [1.1.1] pentyl, bicyclo [2.1.0] pentyl, bicyclo [2.1.1] hexyl or bicyclo [3.1.0] hexyl.
In the present application, ring AIn (c) when ring A is cycloalkyl,/> Ring a in (a) is denoted cycloalkyl. For example/> Ring a in (a) is denoted as cyclopentyl.
In the present application, the term "halogen" means fluorine, chlorine, bromine, iodine, alone or as part of other substituents; fluorine or chlorine is preferred.
The term "alkyl" when used alone or as part of another substituent means a straight or branched hydrocarbon chain group consisting of only carbon and hydrogen atoms, free of unsaturation, having, for example, 1 to 6 carbon atoms, and linked to the remainder of the molecule by a single bond. The term "C 1-C6 alkyl" when used alone or as part of another substituent is understood to mean a straight or branched chain saturated monovalent hydrocarbon radical having 1,2, 3,4, 5 or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-ethylpropyl, 1, 2-dimethylpropyl, neopentyl, 1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 2, 3-dimethylbutyl, 1, 3-dimethylbutyl, or 1, 2-dimethylbutyl, or the like, or an isomer thereof. In particular, the groups have 1,2 or 3 carbon atoms ("C 1-C3 alkyl"), such as methyl, ethyl, n-propyl or isopropyl.
In the present application, the term "alkylene" is understood to mean a straight-chain divalent hydrocarbon group having 1 to 6 carbon atoms or a branched-chain divalent hydrocarbon group having 3 to 6 carbon atoms, unless otherwise specified, such as methylene, ethylene, propylene, 1-methylpropylene, butylene, and the like.
The term "cycloalkyl" alone or as part of another substituent means a cyclic alkyl group. The term "m-n membered cycloalkyl" or "C m-Cn cycloalkyl" is understood to mean a saturated carbocyclic ring having m to n atoms. For example, "3-15 membered cycloalkyl" or "C 3-C15 cycloalkyl" refers to a cyclic alkyl group containing 3 to 15,3 to 9,3 to 6, or 3 to 5 carbon atoms, which may contain 1 to 4 rings. "3-to 10-membered cycloalkyl" contains 3 to 10 carbon atoms. Including monocyclic, bicyclic, tricyclic, spiro, or bridged rings. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl, or a bicyclic hydrocarbon group such as a decalin ring. The term "cycloalkyl" may be used interchangeably with the term "carbocyclyl".
The term "heterocycloalkyl" when used alone or as part of another substituent refers to cycloalkyl groups in which one or more (in some embodiments 1 to 3) carbon atoms are replaced with heteroatoms such as, but not limited to N, O, S and P. The term "m-n membered heterocycloalkyl" or "C m-Cn heterocycloalkyl" is understood to mean a saturated ring having m to n atoms, wherein the heterocyclic atom is selected from N, O, S, P, preferably from N, O or S. For example, the term "4-8 membered heterocycloalkyl" or "C 4-C8 heterocycloalkyl" is understood to mean a saturated ring having 4 to 8 atoms, wherein 1,2, 3 or 4 ring atoms are selected from N, O, S, P, preferably from N, O or S. "4-10 membered heterocycloalkyl" means a saturated ring having 4 to 10 atoms. When a prefix such as 4-8 or 4-10 membered is used to represent a heterocycloalkyl group, the number of carbons is also meant to include heteroatoms. Including monocyclic, bicyclic, tricyclic, spiro, or bridged rings. Examples of heterocycloalkyl groups are: pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, azetidinyl, thiazolidinyl, oxazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepanyl, diazepinyl, oxazepanyl, and the like. The term "heterocycloalkyl" may be used interchangeably with the term "heteroalkyl" ring.
The term "alkynyl", alone or as part of another substituent, refers to a straight or branched chain monovalent hydrocarbon radical of two to forty carbon atoms having at least one carbon-carbon sp triple bond (e.g., C 2-C6 alkynyl, e.g., C 2-C4 alkynyl). Examples of alkynyl groups include, but are not limited to, ethynyl and propynyl.
The term "alkoxy" alone or as part of another substituent refers to the group-O-R X, wherein R X is "alkyl" as defined above.
The term "oxo" when used alone or as part of another substituent means that two hydrogens on the methylene group are replaced with oxygen, i.e., the methylene group is replaced with a carbonyl group; for example when the 2-position of the pyridine in the heteroaryl group is oxo, i.eIs oxo as/>For example, when the 2-position of pyridine is oxo and NH is methyl substituted
The term "aryl" when used alone or as part of another substituent means a monocyclic or polycyclic carbocycle having 6 to 20 carbon atoms, wherein at least one ring is an aromatic ring. When one of the rings is a non-aromatic ring, the groups may be linked through an aromatic ring or through a non-aromatic ring. Examples of aryl groups include, but are not limited to: phenyl, naphthyl, tetrahydronaphthyl, 2, 3-indanyl, biphenyl, phenanthryl, anthracyl and acenaphthylenyl.
The term "heteroaryl ring", alone or as part of another substituent, refers to a monocyclic or polycyclic carbocyclic ring in which at least one ring atom is a heteroatom independently selected from oxygen, sulfur and nitrogen, the remaining ring atoms being C, wherein at least one ring is an aromatic ring. The group may be a carbon group or a heteroatom group (i.e., it may be C-linked or N-linked, as long as it is possible). When one of the rings is a non-aromatic ring, the groups may be linked through an aromatic ring or through a non-aromatic ring. Examples of heteroaryl groups include, but are not limited to: imidazolyl, acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrazolyl, indolyl, benzotriazole, furanyl, thienyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, N-methylpyrrolidinyl, and tetrahydroquinolinyl. The term "heteroaryl" may be used interchangeably with the terms "heteroaromatic", "heteroaryl" or "heteroaryl ring radical".
"Haloalkyl", alone or as part of another substituent, is meant to include branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms substituted with one or more halogens (e.g., -CvFw, where v=1 to 3,w =1 to (2v+1)). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl.
"Deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, alone or as part of another substituent, wherein alkyl is as defined above.
"Deuteroalkoxy" refers to the substitution of the R X moiety in an alkoxy (-O-R X) group with one or more deuterium atoms, either alone or as part of another substituent, wherein R X is "alkyl" as defined above.
In the present application, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, "optionally substituted aryl" means that the aryl group is substituted or unsubstituted, and the description includes both substituted aryl groups and unsubstituted aryl groups.
In the present application, the term "salt" or "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. The term "pharmaceutically acceptable" is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
By "pharmaceutically acceptable acid addition salt" is meant a salt with an inorganic or organic acid that retains the biological effectiveness of the free base without other side effects. By "pharmaceutically acceptable base addition salt" is meant a salt formed with an inorganic or organic base that is capable of maintaining the bioavailability of the free acid without other side effects. In addition to pharmaceutically acceptable salts, other salts are contemplated by the present invention. They may serve as intermediates in the purification of the compounds or in the preparation of other pharmaceutically acceptable salts or may be used in the identification, characterization or purification of the compounds of the invention.
The term "amine salt" refers to the product of neutralizing an alkyl primary, secondary or tertiary amine with an acid. The acid includes an inorganic acid or an organic acid as described in the present application.
The term "solvate" refers to a compound of the invention or a salt thereof that includes a stoichiometric or non-stoichiometric solvent that binds with non-covalent intermolecular forces, and when the solvent is water, is a hydrate.
The term "solvate of a pharmaceutically acceptable salt" refers to a compound formed by combining a compound with a pharmaceutically acceptable acid or base, solvent (including but not limited to water, methanol, ethanol, etc.). The amount of solvent may be stoichiometric or non-stoichiometric. Solvates of pharmaceutically acceptable salts include, but are not limited to: monohydrochloride monohydrate.
The term "prodrug" refers to a compound of the invention that can be converted to a biologically active compound under physiological conditions or by solvolysis. Prodrugs of the invention are prepared by modifying functional groups in the compounds, which modifications may be removed by conventional procedures or in vivo to give the parent compound. Prodrugs include compounds wherein a hydroxyl group or amino group of a compound of the invention is attached to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl group, free amino group, respectively.
In the present application, "pharmaceutical composition" refers to a formulation of a compound of the present application with a medium commonly accepted in the art for delivery of biologically active compounds to a mammal (e.g., a human). The medium includes a pharmaceutically acceptable carrier. The purpose of the pharmaceutical composition is to promote the administration of organisms, facilitate the absorption of active ingredients and further exert biological activity.
In the present application, "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye/colorant, flavoring agent, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonizing agent, solvent, or emulsifying agent that is approved by the relevant government regulatory agency as acceptable for human or livestock use.
The term "adjuvant" refers to a pharmaceutically acceptable inert ingredient. Examples of the category of the term "excipient" include, without limitation, binders, disintegrants, lubricants, glidants, stabilizers, fillers, diluents, and the like. Excipients can enhance the handling characteristics of the pharmaceutical formulation, i.e., by increasing flowability and/or tackiness, making the formulation more suitable for direct compression.
The term "treatment" refers to therapeutic therapy. When specific conditions are involved, treatment refers to: (1) alleviating a disease or one or more biological manifestations of a disorder, (2) interfering with (a) one or more points in a biological cascade that results in or causes a disorder or (b) one or more biological manifestations of a disorder, (3) ameliorating one or more symptoms, effects, or side effects associated with a disorder, or one or more symptoms, effects, or side effects associated with a disorder or treatment thereof, or (4) slowing the progression of a disorder or one or more biological manifestations of a disorder.
The term "preventing" refers to a reduced risk of acquiring or developing a disease or disorder.
The term "patient" refers to any animal, preferably a mammal, that is about to or has received administration of the compound or composition according to embodiments of the present invention. The term "mammal" includes any mammal. Examples of mammals include, but are not limited to, cattle, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., with humans being preferred.
The term "therapeutically effective amount" refers to an amount of a compound that, when administered to a patient, is sufficient to effectively treat a disease or disorder described herein. The "therapeutically effective amount" will vary depending on the compound, the condition and severity thereof, and the age of the patient to be treated, and can be adjusted as desired by those skilled in the art.
The term "inflammatory bowel disease" refers to IBD, and is used to describe diseases involving chronic inflammation of the digestive tract. The main types include: ulcerative colitis and Crohn's disease. Ulcerative colitis. Inflammation and ulcers can be caused by superficial coating of the large intestine (colon) and rectum. Whereas Crohn's disease is characterized by inflammation of the inner lining of the digestive tract, inflammation often involves deep layers of the digestive tract.
The reaction temperature of each step may be appropriately selected depending on the solvent, starting material, reagent, etc., and the reaction time may be appropriately selected depending on the reaction temperature, solvent, starting material, reagent, etc. After the reaction of each step is finished, the target compound can be separated and purified from the reaction system according to a common method, such as filtration, extraction, recrystallization, washing, silica gel column chromatography and the like. Under the condition of not influencing the next reaction, the target compound can also directly enter the next reaction without separation and purification.
The above preferred conditions can be arbitrarily combined on the basis of not deviating from the common knowledge in the art, and thus, each preferred embodiment of the present invention can be obtained.
Advantageous effects
The inventor of the present invention has studied extensively and intensively, and unexpectedly developed a heterocyclic compound or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.
The invention provides a compound, solvate, pharmaceutically acceptable salt, solvate of pharmaceutically acceptable salt or prodrug shown in a formula I, wherein the compound in the formula I has a remarkable inhibiting effect on 15-PGDH. The production of PGE 2 can be significantly increased in a dose-dependent manner and the effect on IPF and liver regeneration is significant. By combining with the pharmacokinetic data of mice, the compound of the invention respectively shows excellent pharmacokinetic properties in the mice, and has higher safety and pharmaceutical properties.
The invention provides a method for preparing a compound shown as I, a solvate, a pharmaceutically acceptable salt, a solvate of the pharmaceutically acceptable salt or a prodrug and an intermediate thereof, wherein the method is simple to operate, high in yield and high in purity, and can be used for medical industrial production.
Detailed Description
The invention will be further illustrated with reference to specific examples. It is to be understood that the following description is only of the most preferred embodiments of the present invention and should not be taken as limiting the scope of the invention. Upon a complete understanding of the present invention, experimental methods without specific references in the following examples, generally according to conventional conditions or according to conditions suggested by the manufacturer, may make insubstantial changes to the technical solutions of the present invention, and such changes should be considered as included in the scope of the present invention.
The application has the following definitions:
Symbol or unit:
IC 50: half inhibition concentration, meaning the concentration at which half of the maximum inhibition effect is achieved
M: mol/L, for example n-butyllithium (14.56 mL,29.1mmol,2.5M in n-hexane) means an n-hexane solution of n-butyllithium at a molar concentration of 2.5mol/L
N: equivalent concentration, e.g. 2N hydrochloric acid means 2mol/L hydrochloric acid solution
Reagent:
TEA: triethylamine
DMSO: dimethyl sulfoxide
Solutol: polyethylene glycol-15 hydroxystearate
Saline: sodium chloride
Example 1: preparation of 6- (1-amino-2- ((2-methoxyethyl) sulfinyl) -7, 8-dihydro-6H-cyclopenta [ d ] thieno [2,3-b ] pyridin-5-yl) -3-methylpyrimidin-4 (3H) -one (compound 1) the synthetic route to the target compound 1 is as follows:
The first step: synthesis of ethyl 2-morpholinocyclopent-1-ene-1-carboxylate (B1-3)
Ethyl 2-oxocyclopentane-1-carboxylate (1-1) (5.0 g,32.01 mmol) and cerium trichloride (789 mg,3.20 mmol) were dissolved in morpholine (4.18 g,48.02 mmol) under nitrogen and stirred at room temperature for 18h. Spin-drying, silica gel column chromatography (PE/EA (V/V) =7/3) gave ethyl 2-morpholinocyclopent-1-ene-1-carboxylate (6.50 g, 90% yield).
LC-MS,M/Z(ESI):226.2[M+H]+。
And a second step of: synthesis of 1-hydroxy-3-mercapto-6, 7-dihydro-5H-cyclopentane [ c ] pyridine-4-carbonitrile (B1-5)
Ethyl 2-morpholino-cyclopent-1-ene-1-carboxylate (6.50 g,28.85 mmol) was dissolved in ethanol (20 mL), to which was added 2-cyanothioacetamide (2.89 g,28.85 mmol) and stirred at room temperature for 18h. The mixture was filtered directly and the filter cake was washed with ethanol (5 ml. Times.2) to give 1-hydroxy-3-mercapto-6, 7-dihydro-5H-cyclopentane [ c ] pyridine-4-carbonitrile (2.21 g, 40% yield).
LC-MS,M/Z(ESI):193.1[M+H]+。
And a third step of: synthesis of 1-hydroxy-3- (((((2-methoxyethyl) thio) methyl) thio) -6, 7-dihydro-5H-cyclopentane [ c ] pyridine-4-carbonitrile (B1-7)
1-Hydroxy-3-mercapto-6, 7-dihydro-5H-cyclopenta [ c ] pyridine-4-carbonitrile (1.0 g,5.20 mmol) was dissolved in acetonitrile (10 mL), to which triethylamine (1.05 g,10.40 mmol) and (chloromethyl) (2-methoxyethyl) sulfane (805 mg,5.72 mmol) were added and stirred at room temperature for 16H. After completion of the reaction, the mixture was diluted with water (10 mL), extracted three times with ethyl acetate (10 mL), and the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by silica gel column chromatography (PE/EA (v/v) =1/1) to give 1-hydroxy-3- (((((2-methoxyethyl) thio) methyl) thio) -6, 7-dihydro-5H-cyclopentane [ c ] pyridine-4-carbonitrile (1.20 g, 78% yield).
LC-MS,M/Z(ESI):297.1[M+H]+。
Fourth step: synthesis of 4-cyano-3- ((((2-methoxyethyl) thio) methyl) thio) -6, 7-dihydro-5H-cyclopenta-di [ c ] pyridin-1-yl triflate (B1-8)
1-Hydroxy-3- (((((2-methoxyethyl) thio) methyl) thio) -6, 7-dihydro-5H-cyclopentane [ c ] pyridine-4-carbonitrile (1.10 g,3.71 mmol) was dissolved in tetrahydrofuran (10 mL), to which was added 1.0M potassium tert-butoxide solution (5.57 mL,5.57 mmol) and N-phenylbis (trifluoromethanesulfonyl) imine (1.59 g,4.45 mmol), stirred at room temperature for 16H after completion of the reaction, diluted with water (10 mL), extracted three times with ethyl acetate (10 mL), and the combined organic phases were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product 4-cyano-3- (((2-methoxyethyl) thio) -6, 7-dihydro-5H-cyclopenta-1-triflate (21.21 g) in yield by column chromatography (PE/EA (v/v) =5/1).
LC-MS,M/Z(ESI):429.2[M+H]+。
Fifth step: synthesis of 3- (((((2-methoxyethyl) thio) methyl) thio) -1- (1-methyl-6-oxo-1, 6-dihydropyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [ c ] pyridine-4-carbonitrile (B1-10)
4-Cyano-3- ((((2-methoxyethyl) thio) methyl) thio) -6, 7-dihydro-5H-cyclopenta-di [ c ] pyridin-1-yl trifluoromethanesulfonate (1.20 g,2.80 mmol), 3-methyl-6- (tributyltin) pyrimidin-4 (3H) -one (1.23 g,3.08 mmol) was dissolved in toluene (20 mL), and bis-tricyclohexylphosphine palladium dichloride (206 mg,0.28 mmol) was added and the reaction mixture was reacted at 110℃for 16H. After the completion of the reaction, the reaction mixture was cooled to room temperature, a saturated potassium fluoride solution (50 mL) was added to the reaction mixture, stirring was continued for 1h, extraction was performed three times with ethyl acetate (50 mL), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by silica gel column chromatography (PE/EA (v/v) =1/2) to give compound 3- ((((2-methoxyethyl) thio) methyl) thio) -1- (1-methyl-6-oxo-1, 6-dihydropyrimidin-4-yl) -6, 7-dihydro-5H-cyclopentane [ c ] pyridine-4-carbonitrile (150 mg, 14% yield).
LC-MS,M/Z(ESI):389.2[M+H]+。
Sixth step: synthesis of 3- ((((2-methoxyethyl) sulfinyl) methyl) thio) -1- (1-methyl-6-oxo-1, 6-dihydropyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [ c ] pyridine-4-carbonitrile (B1-11)
3- ((((2-Methoxyethyl) thio) methyl) thio) -1- (1-methyl-6-oxo-1, 6-dihydropyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [ c ] pyridine-4-carbonitrile (150 mg, 383 umol) was dissolved in chloroform (10 mL) and acetic acid (1 mL), and hydrogen peroxide (66 mg,0.58mmol,30% purity) was added to react at 30℃for 1 hour. After the reaction was completed, it was diluted with water (10 mL), quenched with saturated sodium sulfite solution (10 mL), neutralized with saturated sodium bicarbonate (3 mL), extracted with dichloromethane (20 ml×3), the organic phases were combined, washed with saturated sodium sulfite solution (20 mL), saturated brine (20 mL) in turn, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product, which was purified by column chromatography with DCM/MeOH (v/v) =10/1 to give 3- ((((2-methoxyethyl) sulfinyl) methyl) thio) -1- (1-methyl-6-oxo-1, 6-dihydropyrimidin-4-yl) -6, 7-dihydro-5H-cyclopentane [ c ] pyridine-4-carbonitrile (130 mg, yield 83%).
LC-MS,M/Z(ESI):405.2[M+H]+。
Seventh step: synthesis of 6- (1-amino-2- ((2-methoxyethyl) sulfinyl) -7, 8-dihydro-6H-cyclopentyl [ d ] thieno [2,3-b ] pyridin-5-yl) -3-methylpyrimidin-4 (3H) -one (1)
3- ((((2-Methoxyethyl) sulfinyl) methyl) thio) -1- (1-methyl-6-oxo-1, 6-dihydropyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [ c ] pyridine-4-carbonitrile (130 mg, 321. Mu. Mol) was dissolved in N, N-dimethylformamide (5 mL) and methanol (3 mL), and an aqueous solution (150. Mu.L) of potassium hydroxide (18 mg, 321. Mu. Mol) was added to react at 30℃for 10 minutes. After the completion of the reaction, the mixture was diluted with water (20 mL) and ethyl acetate (20 mL), neutralized with 1N diluted hydrochloric acid (1 mL), extracted with ethyl acetate (20 mL. Times.3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was chromatographed on silica gel with DCM/MeOH (v/v) =10/1 to give 6- (1-amino-2- ((2-methoxyethyl) sulfinyl) -7, 8-dihydro-6H-cyclopentyl [ d ] thieno [2,3-b ] pyridin-5-yl) -3-methylpyrimidin-4 (3H) -one (compound 1) (52 mg, 40% yield).
1H NMR(600MHz,CDCl3)δ8.21(s,1H),7.26(s,1H),5.05(s,2H),3.89–3.84(m,1H),3.70–3.66(m,1H),3.60–3.55(m,4H),3.39(s,3H),3.39–3.32(m,4H),3.30–3.24(m,1H),2.28–2.22(m,2H).
LC-MS,M/Z(ESI):405.1[M+H]+。
EXAMPLE 2 preparation of 6- (1-amino-2- ((2-methoxyethyl) sulfinyl) -8-methyl-7, 8-dihydro-6H-cyclopenta [ d ] thieno [2,3-b ] pyridin-5-yl) -3-methylpyrimidin-4 (3H) -one (Compound 11)
The synthetic route for target compound 11 is as follows:
The first step: synthesis of 3-methyl-2-oxocyclopentane-1-carboxylic acid ethyl ester (B11-3)
2-Methylcyclopent-1-one (B11-1) (1.5 g,15.3 mmol) was dissolved in tetrahydrofuran (20 mL) under nitrogen, naH (1.34 g,33.4mmol, 60%) and diethyl carbonate (3.16 g,26.8 mmol) were added thereto, and the mixture was reacted at 60℃for 10 hours. After completion of the reaction, the mixture was diluted with water (10 mL), extracted three times with ethyl acetate (10 mL), and the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by silica gel column chromatography (PE/EA (v/v) =10/1) to give ethyl 3-methyl-2-oxocyclopentane-1-carboxylate (B11-3) (2.28 g, yield 88%).
And a second step of: synthesis of 1-hydroxy-5-methyl-3-mercapto-6, 7-dihydro-5H-cyclopenta [ c ] pyridine-4-carbonitrile (B11-4)
Ethyl 3-methyl-2-oxocyclopentane-1-carboxylate (B11-3) (2 g,11.75 mmol), potassium t-butoxide (2.64 g,23.5 mmol), 2-cyanothioacetamide (1.76 g,17.63 mmol) was dissolved in 10mL of dimethyl sulfoxide and stirred at 100deg.C for 18h. After completion of the reaction, the mixture was diluted with water (20 mL), extracted three times with ethyl acetate (20 mL), and the organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by column chromatography (DCM/MeOH (v/v) =8/1) to give 1-hydroxy-5-methyl-3-mercapto-6, 7-dihydro-5H-cyclopenta [ c ] pyridine-4-carbonitrile (B11-4) (350 mg, 14% yield).
LC-MS,M/Z(ESI):207.1[M+H]+。
And a third step of: synthesis of 1-hydroxy-5-methyl-3- (2-oxa-5-thia-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B11-5)
1-Hydroxy-5-methyl-3-mercapto-6, 7-dihydro-5H-cyclopenta [ c ] pyridine-4-carbonitrile (B11-4) (1.0 g,4.85 mmol) was dissolved in acetonitrile (10 mL), to which triethylamine (0.98 g,9.70 mmol) and (chloromethyl) (2-methoxyethyl) sulfane (750 mg,5.33 mmol) were added and stirred at room temperature for 16H. After completion of the reaction, the mixture was diluted with water (10 mL), extracted three times with ethyl acetate (10 mL), and the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by column chromatography (PE/EA (v/v) =1/1) to give 1-hydroxy-5-methyl-3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B11-5) (1.10 g, yield 73%).
LC-MS,M/Z(ESI):311.1[M+H]+。
Fourth step: synthesis of 4-cyano-5-methyl-3- (2-oxa-5-thia-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridin-1-yl trifluoromethanesulfonate (B11-6)
1-Hydroxy-5-methyl-3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B11-5) (1.15 g,3.70 mmol) was dissolved in tetrahydrofuran (10 mL), to which was added 1.0M potassium tert-butoxide solution (5.57 mL,5.57 mmol) and N-phenylbis (trifluoromethanesulfonyl) imide (1.59 g,4.45 mmol) and stirred at room temperature for 16H. After completion of the reaction, the mixture was diluted with water (10 mL), extracted three times with ethyl acetate (10 mL), and the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by column chromatography (PE/EA (v/v) =5/1) to give 4-cyano-5-methyl-3- (2-oxa-5-thia-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridin-1-yl trifluoromethanesulfonate (B11-6) (1.05 g, yield 64%).
LC-MS,M/Z(ESI):443.1[M+H]+。
Fifth step: synthesis of 5-methyl-1- (1-methyl-6-oxopyrimidin-4-yl) -3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B11-7)
4-Cyano-5-methyl-3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridin-1-yl trifluoromethanesulfonate (B11-6) (1.00 g,2.26 mmol), 3-methyl-6- (tributylstannyl) pyrimidin-4 (3H) -one (1.35 g,3.39 mmol) was dissolved in toluene (10 mL), and bis (tricyclohexylphosphine) palladium dichloride (181 mg,0.23 mmol) was added and the reaction solution was reacted at 110℃for 16H. After the completion of the reaction, the reaction mixture was cooled to room temperature, a saturated potassium fluoride solution (50 mL) was added to the reaction mixture, stirring was continued for 1h, extraction was performed three times with ethyl acetate (50 mL), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by column chromatography (PE/EA (v/v) =1/2) to give 5-methyl-1- (1-methyl-6-oxopyrimidin-4-yl) -3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B11-7) (120 mg, yield 13%).
LC-MS,M/Z(ESI):403.2[M+H]+。
Sixth step: synthesis of 3- ((((2-methoxyethyl) (oxy) -lambda 4 -thio ] methyl } thio) -5-methyl-1- (1-methyl-6-oxopyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B11-8)
5-Methyl-1- (1-methyl-6-oxopyrimidin-4-yl) -3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B11-7) (120 mg, 300. Mu. Mol) was dissolved in chloroform (10 mL) and acetic acid (1 mL), and hydrogen peroxide (20 mg,0.60mmol,30% purity) was added to react at 30℃for 1 hour. After the completion of the reaction, diluted with water (10 mL), quenched with saturated sodium sulfite solution (10 mL), neutralized with saturated sodium bicarbonate (3 mL), extracted with dichloromethane (20 ml×3), the organic phases were combined, washed successively with saturated sodium sulfite solution (20 mL), saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (DCM/MeOH (v/v) =10/1) to give 3- ((((2-methoxyethyl) (oxy) - λ 4 -thio ] methyl } thio) -5-methyl-1- (1-methyl-6-oxypyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B11-8) (100 mg, yield 80%).
LC-MS,M/Z(ESI):419.2[M+H]+
Seventh step: synthesis of 6- (1-amino-2- ((2-methoxyethyl) sulfinyl) -8-methyl-7, 8-dihydro-6H-cyclopenta [ d ] thieno [2,3-b ] pyridin-5-yl) -3-methylpyrimidin-4 (3H) -one (Compound 11)
3- ((((2-Methoxyethyl) (oxy) - λ 4 -thio ] methyl } thio) -5-methyl-1- (1-methyl-6-oxopyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B11-8) (100 mg,0.24 mmol) was dissolved in N, N-dimethylformamide (5 mL) and methanol (3 mL), an aqueous solution of potassium hydroxide (10 mg,0.24 mmol) (150 μl) was added and reacted at 30 ℃ for 10 min after completion of the reaction, diluted with water (20 mL) and ethyl acetate (20 mL), neutralized with 1N diluted hydrochloric acid (1 mL), ethyl acetate (20 ml×3) was extracted, the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product by column chromatography (DCM/MeOH (v/v) 10/1), freeze-dried to give 6- (1-amino-2- ((2-methoxyethyl) sulfinyl) -8-methyl-8-dihydro [ 7-6-cyclopenta [ 3-5H ] pyridine (3 mg) and (50 mg) of the product.
LC-MS,M/Z(ESI):419.2[M+H]+
1H NMR(400MHz,CDCl3)δ8.21(s,1H),7.28(d,1H),5.08(s,2H),3.92–3.84(m,1H),3.83–3.75(m,1H),3.70(dt,1H),3.65–3.55(m,4H),3.43–3.33(m,5H),3.32–3.24(m,1H),2.40–2.26(m,1H),2.02(dd,1H),1.35(dd,3H).
Example 3: preparation of 6- (1-amino-2- ((2-methoxyethyl) sulfinyl) -8, 8-dimethyl-7, 8-dihydro-6H-cyclopenta [1,2-d ] thieno [2,3-b ] pyridin-5-yl) -3-methyl-3, 4-dihydropyrimidin-4-one (Compound 12)
The synthetic route for target compound 12 is as follows:
the first step: synthesis of ethyl 3, 3-dimethyl-2-oxocyclopentane-1-carboxylate (B12-2)
/>
2, 2-Dimethylcyclopent-1-one (B12-1) (2 g,17.8 mmol) was dissolved in tetrahydrofuran (20 mL) under nitrogen, naH (1.43 g,35.66mmol, 60%) and diethyl carbonate (10.53 g,89.15 mmol) were added thereto and reacted at 60℃for 18 hours. After completion of the reaction, the mixture was diluted with water (10 mL), extracted three times with ethyl acetate (10 mL), and the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by column chromatography (PE/EA (v/v) =10/1) to give ethyl 3, 3-dimethyl-2-oxocyclopentane-1-carboxylate (B12-2) (2.50 g, yield 82%).
And a second step of: synthesis of 1-hydroxy-5, 5-dimethyl-3-mercapto-6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-3)
Ethyl 3, 3-dimethyl-2-oxocyclopentane-1-carboxylate (B12-2) (2 g,10.86 mmol), potassium t-butoxide (3.05 g,27.14 mmol), 2-cyanothioacetamide (2.17 g,21.71 mmol) was dissolved in dimethyl sulfoxide (10 mL) and stirred at 120℃for 18h. After completion of the reaction, the mixture was diluted with water (20 mL), extracted three times with ethyl acetate (20 mL), and the organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by column chromatography (DCM/MeOH (v/v) =8/1) to give 1-hydroxy-5, 5-dimethyl-3-mercapto-6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-3) (210 mg, yield 9%).
LC-MS,M/Z(ESI):221.1[M+H]+。
And a third step of: synthesis of 1-hydroxy-5, 5-dimethyl-3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-4)
1-Hydroxy-5, 5-dimethyl-3-mercapto-6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-3) (2.0 g,9.1 mmol) was dissolved in acetonitrile (20 mL), and triethylamine (1.84 g,18.16 mmol) and (chloromethyl) (2-methoxyethyl) sulfane (1.40 g,9.99 mmol) were added thereto and stirred at room temperature for 16H. After completion of the reaction, the mixture was diluted with water (10 mL), extracted three times with ethyl acetate (10 mL), and the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by column chromatography (PE/EA (v/v) =1/1) to give 1-hydroxy-5, 5-dimethyl-3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-4) (1.88 g, yield 64%).
LC-MS,M/Z(ESI):325.1[M+H]+。
Fourth step: synthesis of 4-cyano-5, 5-dimethyl-3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridin-1-yl trifluoromethane sulfonate (B12-5)
1-Hydroxy-5, 5-dimethyl-3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-4) (1.20 g,3.70 mmol) was dissolved in tetrahydrofuran (10 mL), to which was added 1.0M potassium tert-butoxide solution (5.57 mL,5.57 mmol) and N-phenylbis (trifluoromethanesulfonyl) imine (1.59 g,4.45 mmol) and stirred at room temperature for 16H. After completion of the reaction, the mixture was diluted with water (10 mL), extracted three times with ethyl acetate (10 mL), and the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by column chromatography (PE/EA (v/v) =5/1) to give 4-cyano-5, 5-dimethyl-3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridin-1-yl trifluoromethanesulfonate (B12-5) (1.00 g, yield 59%).
LC-MS,M/Z(ESI):457.1[M+H]+。
Fifth step: synthesis of 5, 5-dimethyl-1- (1-methyl-6-oxopyrimidin-4-yl) -3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-6)
4-Cyano-5, 5-dimethyl-3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridin-1-yl trifluoromethane sulfonate (B12-5) (1.00 g,2.19 mmol), 3-methyl-6- (tributylstannyl) pyrimidin-4 (3H) -one (1.20 g,2.63 mmol) was dissolved in toluene (10 mL), and bis (tricyclohexylphosphine) palladium dichloride (178 mg,0.22 mmol) was added and the reaction mixture was reacted at 110℃for 16H. After the completion of the reaction, the reaction mixture was cooled to room temperature, a saturated potassium fluoride solution (50 mL) was added to the reaction mixture, stirring was continued for 1h, extraction was performed three times with ethyl acetate (50 mL), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by column chromatography (PE/EA (v/v) =1/2) to give 5, 5-dimethyl-1- (1-methyl-6-oxopyrimidin-4-yl) -3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-6) (90 mg, yield 10%).
LC-MS,M/Z(ESI):417.2[M+H]+。
Sixth step: synthesis of 3- ((((2-methoxyethyl) (oxy) -lambda 4 -thio) methyl) thio) -5, 5-dimethyl-1- (1-methyl-6-oxopyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-7)
5, 5-Dimethyl-1- (1-methyl-6-oxopyrimidin-4-yl) -3- (2-oxa-5-thiahex-6-ylsulfanyl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-6) (90 mg, 0.22. Mu. Mol) was dissolved in chloroform (10 mL) and acetic acid (1 mL), and hydrogen peroxide (16 mg,0.44mmol,30% purity) was added to react at 30℃for 1 hour. After the reaction was completed, it was diluted with water (10.0 mL), quenched with saturated sodium sulfite solution (10 mL), neutralized with saturated sodium bicarbonate (3 mL), extracted with dichloromethane (20 ml×3), the organic phases were combined, washed successively with saturated sodium sulfite solution (20 mL), saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (DCM/MeOH (v/v) =10/1) to give 3- ((((2-methoxyethyl) (oxy) - λ 4 -thio) methyl) thio) -5, 5-dimethyl-1- (1-methyl-6-oxypyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-7) (70 mg, yield 75%).
LC-MS,M/Z(ESI):433.2[M+H]+
Seventh step: synthesis of 6- (1-amino-2- ((2-methoxyethyl) sulfinyl) -8, 8-dimethyl-7, 8-dihydro-6H-cyclopenta [1,2-d ] thieno [2,3-b ] pyridin-5-yl) -3-methyl-3, 4-dihydropyrimidin-4-one (Compound 12)
3- ((((2-Methoxyethyl) (oxy) -lambda 4 -thio) methyl) thio) -5, 5-dimethyl-1- (1-methyl-6-oxopyrimidin-4-yl) -6, 7-dihydro-5H-cyclopenta [1,2-c ] pyridine-4-carbonitrile (B12-7) (70 mg,0.16 mmol) was dissolved in N, N-dimethylformamide (5 mL) and methanol (3 mL), and an aqueous solution (150. Mu.L) of potassium hydroxide (10 mg,0.24 mmol) was added and reacted at 30℃for 10 minutes. After the completion of the reaction, the mixture was diluted with water (20 mL) and ethyl acetate (20 mL), neutralized with 1N diluted hydrochloric acid (1 mL), extracted with ethyl acetate (20 mL. Times.3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was lyophilized by column chromatography (DCM/MeOH (v/v) =10/1) to give 6- (1-amino-2- ((2-methoxyethyl) sulfinyl) -8, 8-dimethyl-7, 8-dihydro-6H-cyclopenta [1,2-d ] thieno [2,3-b ] pyridin-5-yl) -3-methyl-3, 4-dihydropyrimidin-4-one (compound 12) (40 mg, 57% yield).
LC-MS,M/Z(ESI):433.2[M+H]+
1H NMR(400MHz,CDCl3)δ8.28(s,1H),6.61(s,1H),5.03(s,2H),3.83(ddd,1H),3.67–3.60(m,4H),3.54(dd,1H),3.37(s,3H),3.26–3.17(m,1H),2.85(t,2H),2.01(t,2H),1.36(s,6H).
The following target compounds were prepared analogously to the synthetic method of reference compound 1.
/>
/>
Test example 1: compounds for 15-PGDH enzyme inhibition assay
15-PGDH (R & D Systems, cat. No. 5660-DH-010) was configured to a final concentration of 2-fold, i.e.30 nM, with Assay Buffer (50 mM Tris-HCl, pH 7.5,0.01 vol% Tween 20). Then add to 384 white plates (Cisbio Bioassays, cat 66PL 384025) at 8 μl/well. Negative control wells were set and Assay Buffer alone was added without enzyme. The compound was then formulated with Assay Buffer to a final concentration of 4-fold, i.e., 4000nM starting, 3-fold dilution, 10 concentrations. Add 4. Mu.l/well to the above-mentioned white plate, mix well, centrifuge at 1000rpm for 1min, incubate at 25℃for 10min. Positive control wells (with 15-PGDH only) and negative control wells (without 15-PGDH) were set simultaneously. The mixture of NAD + (Sellect. Cat# S2518) and PGE 2 (R & D Systems, cat# 2296/10) was then prepared with an Assay Buffer. NAD + and PGE 2 were configured to 4 times the final concentration, i.e., 2mM and 0.12mM, respectively, using an Assay Buffer. Then, 4. Mu.l/well of the mixture was added to the above-mentioned white plate, and after mixing, the mixture was centrifuged at 1000rpm for 1min and incubated at 25℃for 30min to effect a reaction. The excitation wavelength was 340nm and the emission wavelength was 485nm using an instrument TECAN SPARK M. IC 50 values were calculated by four-parameter fitting with GRAPHPAD PRISM 8.0.0.
Results of the 15-PGDH inhibition test by the compounds of Table 1
Numbering of compounds IC50(nM)
Compound 1 1.5
Compound 11 1.26
Experimental results show that the compound has remarkable inhibition effect on 15-PGDH.
Test example 2: effect of Compounds on PGE 2 levels in A549 cell supernatants
A549 cells (wufanuosai) were cultured in f12k+10% fbs, cells with good cell status at log phase were taken for experiment, the cells were digested and counted, and the cells were inoculated into 24-well plates, 8000 cells/well. Cells were incubated overnight at 37℃in a 5% CO 2 incubator. After the cells had adhered, the medium containing 0.5% FBS was changed and treated for about 10 hours, IL-1β (final concentration 20ng/mL,1 mL/well) was added to each well, while a control group (control group was not added with IL-1β) was set. After IL-1β stimulation for about 24 hours, the cell culture broth from each well was aspirated, and each well was gently washed with fresh 0.5% FBS-containing medium, and then 400. Mu.L of medium containing each concentration of the compound (20 nM and 2500 nM) was added to each well for about 12 hours. The supernatants were collected and assayed for PGE 2 using ELISA kit (R & D Systems, cat. KGE 004B).
Table 2 Compounds fold increase in PGE2 in A549 cell supernatants
Compound number/concentration 20nM 2500nM
Compound 1 2.52 6.11
Compound 11 3.59 5.01
Experimental results show that the compound can significantly increase the generation of PGE 2.
Test example 3: mouse IPF prevention model efficacy experiment
Male mice are adaptively fed for 1-2 weeks, after the weight reaches the standard (25 g), a certain dose of bleomycin is used for inducing an IPF model (idiopathic pulmonary fibrosis model), the model is randomly divided into a model group and a dosing group according to the weight of animals on the day of model building, and daily oral gastric lavage dosing is started, and a vehicle control group is given with a blank vehicle for 21 days. During the dosing period, body weight was weighed every 3 days. Animals were euthanized at the end of the last day of dosing, lungs were removed from the thyroid cartilage (without perfusion), 10% formalin was slowly perfused into the lungs to double-sided lung filling, the main trachea was ligated and fixed in 5-10 times tissue volume of 10% formalin, left lungs were paraffin tissue section-stained, HE stained, masson Trichrome stained, section panoramic scan was performed using Hamamatsu NanoZoomer Digital Pathology (S210) section scanner, and pathology analysis was performed.
TABLE 3 evaluation index of pulmonary fibrosis pathology
Experimental results show that the compound of the invention can significantly reduce the fibrosis degree of the mice IPF prevention model.
Test example 4: mouse IPF treatment model efficacy experiment
Male mice are adaptively fed for 1-2 weeks, after the weight reaches the standard (25 g), a certain dose of bleomycin is used for inducing an IPF model (idiopathic pulmonary fibrosis model), the model is randomly divided into a model group and a dosing group according to the weight of animals on the Day of model building, day7 starts to orally irrigate the stomach every Day, and a vehicle control group is dosed with a blank vehicle for 14 days. During the dosing period, body weight was weighed 2 times per week. Animals were euthanized at the end of the last day of dosing, lungs were removed from the thyroid cartilage (without perfusion), 10% formalin was slowly perfused into the lungs to double-sided lung filling, the main trachea was ligated and fixed in 5-10 times tissue volume of 10% formalin, left lungs were paraffin tissue section-stained, HE stained, masson Trichrome stained, section panoramic scan was performed using Hamamatsu NanoZoomer Digital Pathology (S210) section scanner, and pathology analysis was performed.
TABLE 4 evaluation index of pulmonary fibrosis pathology
Experimental results show that the compound of the invention can significantly reduce the fibrosis degree of a mouse IPF treatment model.
Test example 5: mouse liver excision regeneration efficacy experiment
8 Week old male C57BL/6J mice (20-24 g), animals were anesthetized, abdomen was fixed up, surgical sites were shaved and sterilized with iodophor; the abdomen transects the opening about 1.5 cm to 2cm, and clamps the abdominal wall arteries at two sides by a hemostatic clamp; opening the abdominal cavity, freeing each hepatic lobe, binding the hepatic portal part of the hepatic lobe to be resected by an operation line, and resecting the left outer lobe and the middle lobe of the liver after the color of the hepatic portal part is darkened; after the residual blood of the abdominal cavity is cleaned after the operation, the myolayer and the fur layer are sewn layer by layer; care was taken for post-operative care. Animals were sacrificed on day 1 and 3, respectively, and intact liver tissues were weighed and compared with model groups to evaluate the effect of the drug on promoting liver regeneration.
Experimental results show that the compound of the invention can remarkably promote liver regeneration.
Test example 6: mouse pharmacokinetics
The pharmacokinetic properties of the compounds of the invention were determined with reference to the following experimental methods.
Adopts male CD-1 mice, the dosage is 10mg/kg, the administration route is gastric lavage, and the solvent is
5% DMSO+10% Solutol+85% Saline, overnight fast, and blood collection time points are 15, 30 minutes and 1,2, 4, 6, 8, 24 hours before and after administration. Blood samples 6800g were centrifuged at 2-8deg.C for 6 minutes, and plasma was collected and stored at-80deg.C. 10. Mu.L of plasma at each time point was taken, 200. Mu.L of methanol containing 100ng/mL of internal standard was added, and after vortexing and mixing, 18000g was centrifuged for 7 minutes at 2-8 ℃. 200 μl was transferred to a 96-well sample plate for quantitative LC-MS/MS analysis. The principal pharmacokinetic parameters were analyzed using the WinNonlin 7.0 software non-compartmental model.
Experimental results show that the compound of the invention shows excellent pharmacokinetic properties in mice.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.

Claims (29)

1. A heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof:
Wherein,
Ring a is a C 3-C20 alicyclic hydrocarbon group;
R a is H, halogen, hydroxy, amino, nitro, cyano, carbonyl, oxo, carboxy, C 1-C6 alkyl, -NH (C 1-C6 alkyl), C 1-C6 deuterated alkyl, C 2-C6 alkynyl, halogenated C 1-C6 alkyl, hydroxyC 1-C6 alkyl, C 1-C6 alkylcarbonyl, C 1-C6 alkoxy or halogenated C 1-C6 alkoxy; when R a is a plurality of substituents, the substituents are the same or different;
r 1 is C 1-C6 alkyl, C 1-C6 deuterated alkyl, halogenated C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), C 1-C6 alkoxy, - (C 1-C6 alkylene) - (C 1-C6 alkoxy), 3-11 membered heterocycloalkyl, or- (C 1-C6 alkylene) - (3-11 membered heterocycloalkyl); and, the R 1 is optionally substituted with one or more R 1-1; when there are a plurality of substituents, the substituents may be the same or different;
R 1-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, C 1-C6 alkyl, C 1-C6 deuterated alkyl, halogenated C 1-C6 alkyl, C 1-C6 alkoxy or deuterated C 1-C6 alkoxy;
R 2 is amino, CN or-NHC (O) alkyl;
R 3 is aryl, 3-11 membered heterocycloalkyl, or 3-11 membered heteroaryl, optionally substituted with one or more R 3-1; when there are a plurality of substituents, the substituents may be the same or different; the heteroatom is selected from one or more of N, O, S;
R 3-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-N (R 3-1-1)2、-N(R3-1-1)2、-N(R3-1-1) (alkylene-OH), -N (R 3-1-1) (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halo C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C8 cycloalkyl, 3-11 membered heterocycloalkyl, -C (O) N (R 3-1-1)2、-C(O)N(R3-1-1) (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halo C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) p-C1-C6 alkyl, or-S (=O) (= NR 3-1-1)-R3-1-1, wherein the C 3-C8 cycloalkyl and the 3-11 membered heterocycloalkyl are each optionally substituted by R 3-1-2;
Each R 3-1-1 is independently H, C 1-C6 alkyl or alkylene-OH, optionally substituted with: -OH, -alkylene-NH 2, -alkylene-N (R 3-1-3) 2, -alkylene-O-alkylene-OH, -alkylene-O-alkylene-NH 2, -C (O) -alkyl, -C (O) O-alkyl, -alkylene-COOH or-S (O) p -alkyl; or alternatively, in-O-alkylene-N (R 3-1-1)2 or-N (R 3 -1-1)2, two R 3-1-1 together with the N atom to which they are attached form a 4-7 membered heterocyclic ring, optionally containing a further heteroatom selected from O, S, or N, and wherein the 4-7 membered heterocyclic ring is optionally substituted with R 3-1-4; or alternatively, in-S (=o) (=nr 3-1-1)-R3-1-1, two R 3-1-1 together with the N and S atoms to which they are attached form a 4-7 membered heterocyclic ring);
R 3-1-2 is hydroxy, halogen, C 1-C6 alkyl or C 1-C6 alkoxy;
R 3-1-3 is H or C 1-C6 alkyl, or two R 3-1-3 together with the N atom to which they are attached may form a 4-7 membered heterocyclic ring, the 4-7 membered heterocyclic ring optionally containing a further heteroatom selected from O, S (O) r or N;
r 3-1-4 is halogen, C 1-C6 alkyl or C 1-C6 alkoxy;
m, n, p, r is 0, 1 or 2, respectively.
2. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I satisfies one or more of the following conditions:
(1) R 1 is C 1-C6 alkyl, C 1-C6 deuterated alkyl, halogenated C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), C 1-C6 alkoxy, - (C 1-C6 alkylene) - (C 1-C6 alkoxy), 3-11 membered heterocycloalkyl, or- (C 1-C6 alkylene) - (3-11 membered heterocycloalkyl); and, the R 1 is optionally substituted with one or more R 1-1; when there are a plurality of substituents, the substituents may be the same or different; the heteroatom of the heterocycloalkyl group is selected from one or more of N, O, S, and the number of the heteroatom is 1,2 or 3;
(2) R 1-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, C 1-C6 alkyl, C 1-C6 deuterated alkyl, halogenated C 1-C6 alkyl, C 1-C6 alkoxy or deuterated C 1-C6 alkoxy; the alkylene is a C 1-C6 alkylene;
(3) R 2 is amino, CN or-NHC (O) alkyl; the alkyl is a C 1-C6 alkyl;
(4) R 3 is aryl, 3-11 membered heterocycloalkyl, or 3-11 membered heteroaryl, optionally substituted with one or more R 3-1; when there are a plurality of substituents, the substituents may be the same or different; the hetero atoms in the heterocycloalkyl and heteroaryl are selected from one or more of N, O, S, and the number of the hetero atoms is 1,2 or 3; the aryl is 6-10 membered aryl;
(5) R 3-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-N (R 3-1-1)2、-N(R3-1-1)2、-N(R3-1-1) (alkylene-OH), -N (R 3-1-1) (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halo C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C8 cycloalkyl, 3-11 membered heterocycloalkyl, -C (O) N (R 3-1-1)2、-C(O)N(R3-1-1) (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halo C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) p-C1-C6 alkyl or-S (=O) (=NR 3-1-1)-R3-1-1), wherein each of said C 3-C8 cycloalkyl and said 3-11 membered heterocycloalkyl is optionally substituted by R 3-1-2, said alkylene is C 1-C6 alkylene, said alkyl is C 1-C6 alkyl, said heteroatom is one or more than one heteroatom selected from the group consisting of N, O, S,1 or 2 heteroatoms selected from the group
(6) Each R 3-1-1 is independently H, C 1-C6 alkyl or alkylene-OH, optionally substituted with: -OH, -alkylene-NH 2, -alkylene-N (R 3-1-3) 2, -alkylene-O-alkylene-OH, -alkylene-O-alkylene-NH 2, -C (O) -alkyl, -C (O) O-alkyl, -alkylene-COOH or-S (O) p -alkyl; or alternatively in-O-alkylene-N (R 3-1-1)2 or-N (R 3 -1-1)2, two R 3-1-1 together with the N atom to which they are attached form a 4-7 membered heterocyclic ring containing N and optionally containing a heteroatom of O or S, and wherein the 4-7 membered heterocyclic ring is optionally substituted with R 3-1-4; or alternatively in-S (=o) (=nr 3-1-1)-R3-1-1, two R 3-1-1 together with the N and S atoms to which they are attached form a 4-7 membered heterocyclic ring; the alkylene is C 1-C6 alkylene; the alkyl is C 1-C6 alkyl), and
(7) R 3-1-3 is H or C 1-C6 alkyl, or two R 3-1-3 together with the N atom to which they are attached can form a 4-7 membered heterocyclic ring containing N and optionally a heteroatom containing O or S (O) r.
3. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof according to claim 1, wherein ring a is a C 3-C12 alicyclic hydrocarbon group, preferably ring a is a C 3-C7 alicyclic hydrocarbon group.
4. A heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof according to claim 3, wherein ring a is cyclopentyl, cyclohexyl, bicyclo [3.1.0] hexyl or spiro [2.4] heptane.
5. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof according to claim 1, wherein R a is methyl.
6. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof, as claimed in claim 1, wherein R 1 is C 1-C4 alkyl, C 1-C4 deuteroalkyl, halogenated C 1-C4 alkyl, C 3-C6 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C6 cycloalkyl), C 1-C4 alkoxy, - (C 1-C4 alkylene) - (C 1-C4 alkoxy), 3-6 membered heterocycloalkyl, or- (C 1-C4 alkylene) - (3-6 membered heterocycloalkyl); and, the R 1 is optionally substituted with one or more R 1-1; when there are a plurality of substituents, the substituents may be the same or different; said R 1-1 has the definition of claim 1;
Preferably, R 1 is butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, - (CH 2)x -cyclopropyl, - (CH 2) x -cyclobutyl, - (CH 2)x -cyclopentyl, - (CH 2) x -cyclohexyl or- (C 1-C4 alkylene) - (C 1-C4 alkoxy), wherein x is 1,2 or 3.
7. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof, as claimed in claim 1, wherein R 1-1 is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C3 alkyl), -O-alkylene-OH, C 1-C3 alkyl, deuterated C 1-C6 alkyl, halogenated C 1-C3 alkyl, C 1-C3 alkoxy, or deuterated C 1-C3 alkoxy.
8. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 1, wherein R 2 is-NH 2, CN, or-NH-C (O) -CH 3.
9. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof according to claim 1 or 2, wherein R 3 is a 5-6 membered heterocycloalkyl or a 5-10 membered heteroaryl, optionally substituted with one or more R 3-1, and R 3-1 has the definition as claimed in claim 1 or 2.
10. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 1 or 2, wherein R 3 is a 5-6 membered heteroaryl optionally substituted with one or more R 3-1, or is an 8-10 membered bicyclic heteroaryl optionally substituted with one or more R 3-1, and R 3 -1 has the definition as defined in claim 1 or 2.
11. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 1, wherein R 3-1 is H, methyl, oxo, -NHCH 3, or-S (=o) (=nch 3)-CH3).
12. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I has a structure of formula I-1:
Wherein X 1、X2、X3、X4 and X 5 each independently represent a ring atom;
X 1、X2、X3、X4 and X 5 are each independently N, O, S, CH 2, CH or C;
The bond connected between X 4、X5 is a single bond or a double bond;
B is absent or B forms together with the X 4、X5 ring atom a 3-7 membered heterocycloalkyl, 5 membered heteroaryl or 6 membered heteroaryl ring; the heteroatom is selected from one or more of N, O, S;
R b、Rc is each independently H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-N (R 3-1-1)2、-N(R3-1-1)2、-N(R3-1-1) (alkylene-OH), -N (R 3-1-1) (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halo C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C8 cycloalkyl, 3-11 membered heterocycloalkyl, -C (O) N (R 3-1-1)2、-C(O)N(R3-1-1) (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halo C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) p-C1-C6 alkyl, or-S (=O) (=NR 3 -1-1)-R3-1-1; when the R b or R c are a plurality of substituents, the substituents are the same or different;
s and t are respectively 0, 1 or 2;
R 1、R2、R3-1-1、Ra, p and m have the definition as defined in claim 1.
13. The heterocyclic compound of formula I-1, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 12, wherein the heterocyclic compound of formula I-1 satisfies one or more of the following conditions:
(1) B is absent or B forms together with the X 4、X5 ring atom a 3-7 membered heterocycloalkyl, 5 membered heteroaryl or 6 membered heteroaryl ring; the heteroatoms in the heterocycloalkyl and heteroaryl groups are selected from one or more of N, O, S;
(2) The alkylene is a C 1-C6 alkylene; and
(3) The saidSelected from 6 membered heteroaryl groups containing 1 or more heteroatoms, 6 membered heteroaryl and 3-7 membered heterocycloalkyl, 6 membered heteroaryl and 5-6 membered heteroaryl; the heteroatom is selected from N, O or S;
Preferably, the said Selected from the group consisting of pyridine, pyrimidine, pyridazine, pyridocyclobutyl, pyridocyclopentyl, pyridoimidazole, pyridopyrazole, pyridofuran, pyridopyrimidine, pyridothiophene, pyridothiazole;
Preferably, the said Selected from pyridine, pyrimidine, pyridopyrazole;
More preferably, the Selected from pyridine, pyrimidine,/>
14. The heterocyclic compound of formula I according to claim 12, wherein R b、Rc is each independently H, halogen, hydroxy, amino, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-NH 2, -NH (alkylene-OH), -NH (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halogenated C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C6 cycloalkyl, 3-7 membered heterocycloalkyl, -C (O) NH 2, -C (O) NH (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halogenated C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) 2-C1-C6 alkyl or-S (=c 3)-C1-C6 alkyl) (-C3742 alkyl, preferably ncoalkyl.
15. The heterocyclic compound of formula I according to claim 12, wherein each R b、Rc is independently H, oxo, C 1-C4 alkyl, -NH (C 1-C4 alkyl), C 1-C4 deuteroalkyl, C 2-C4 alkynyl, halogenated C 1-C4 alkyl, hydroxyc 1-C4 alkyl, C 1-C4 alkoxy, halogenated C 1-C4 alkoxy;
Preferably, each R b、Rc is independently H, oxo, methyl, -NHCH 3、-S(＝O)(＝NCH3)-CH3.
16. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I has a structure of formula I-2:
wherein X 1、X2、X3 and X 4 each independently represent a ring atom;
X 1、X2、X3 and X 4 are each independently N, O, S, CH 2, CH or C;
R b is H, halogen, hydroxy, nitro, cyano, carbonyl, oxo, carboxy, -NH (C 1-C6 alkyl), -O-alkylene-OH, -O-alkylene-N (R 3-1-1)2、-N(R3-1-1)2、-N(R3-1-1) (alkylene-OH), -N (R 3-1-1) (alkylene-O-alkyl), C 1-C6 alkyl, C 1-C6 deuteroalkyl, C 2-C6 alkynyl, -alkylene-OH, halo C 1-C6 alkyl, hydroxy C 1-C6 alkyl, C 3-C8 cycloalkyl, 3-11 membered heterocycloalkyl, -C (O) N (R 3-1-1)2、-C(O)N(R3-1-1) (alkylene-OH), -C (O) -C 1-C6 alkyl, C 1-C6 alkoxy, halo C 1-C6 alkoxy, -C (O) O-C 1-C6 alkyl, -S (O) p-C1-C6 alkyl, or-S (=O) (=NR 3-1-1)-R3-1-1; when said R b is a plurality of substituents, said substituents are the same or different;
s is 0,1 or 2;
R 1、R2、R3-1-1、Ra, p and m have the definition as defined in claim 1.
17. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof according to claim 16, wherein the heterocyclic compound isFor/>
And/or, the alkylene is a C 1-C6 alkylene.
18. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I satisfies one or more of the following conditions:
(1) The halogen is F, cl, br or I;
(2) The alkyl is a C 1-C6 alkyl, preferably a C 1-C4 alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
(3) The C 1-C6 haloalkyl is-CvFw, wherein v = 1 to 3,w = 1 to (2v+1), such as trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2-trifluoroethyl, heptafluoropropyl, or heptachloropropyl;
(4) The C 3-C8 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl;
(5) The alkylene is a C 1-C6 alkylene, preferably a C 1-C4 alkylene, such as methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, sec-butylene or tert-butylene;
(6) The C 1-C6 alkoxy group is a C 1-C4 alkoxy group such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy;
(7) The 3-11 membered heterocycloalkyl is a 5-6 membered heterocycloalkyl;
(8) The heteroatom of the 3-11 membered heterocycloalkyl is selected from one or more of N, O, S; the number of the hetero atoms is 1, 2 or 3;
(9) The aryl in R 3 is a 6-10 membered aryl, such as phenyl or naphthyl;
(10) The heteroatom in R 3 is a heteroatom in the 3-11 membered heterocycloalkyl or 3-11 membered heteroaryl;
(11) The 4-7 membered heterocycle is 4-7 membered heterocycloalkyl; and
(12) The heteroatom of the 4-7 membered heterocycle is selected from one or more of N, O, S; the number of heteroatoms is 1, 2 or 3.
19. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I satisfies one or more of the following conditions:
(1) Ring a is C 3-C7 cycloalkyl;
(2) R 1 is C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), C 1-C4 alkoxy, - (C 1-C6 alkylene) - (C 1-C6 alkoxy); and, the R 1 is optionally substituted with one or more R 1-1; when there are a plurality of substituents, the substituents may be the same or different;
Preferably, R 1 is C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), - (C 1-C6 alkylene) - (C 1-C6 alkoxy);
More preferably, R 1 is
(3) R 2 is amino;
(4) R 3 is 3-11 membered heterocycloalkyl or 3-11 membered heteroaryl, optionally substituted with one or more R 3-1; when there are a plurality of substituents, the substituents may be the same or different; the heteroatom in the 3-11 membered heterocycloalkyl or 3-11 membered heteroaryl is selected from one or more of N, O, S; the number of the hetero atoms is 1,2 or 3;
Preferably, R 3 is Each of which is optionally substituted with one or more of R 3-1 described above;
More preferably, R 3 is
(5) Each R 3-1 is independently C 1-C6 alkyl, oxo, -NH (C 1-C6 alkyl), or-S (=O) (=NR 3-1-1)-R3-1-1, and
(6) Each R 3-1-1 is independently H, C 1-C6 alkyl or C 1-C6 alkylene-OH.
20. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to claim 1, wherein the heterocyclic compound of formula I satisfies one of the following schemes one, two, and three:
Scheme one:
the heterocyclic compound shown in the formula I is a heterocyclic compound shown in the formula I-7,
Wherein ring A is a C 3-C7 alicyclic hydrocarbon group;
Each R a is independently C 1-C6 alkyl;
m is 0,1 or 2;
R 1 is C 1-C6 alkyl, C 3-C8 cycloalkyl, - (C 1-C6 alkylene) - (C 3-C8 cycloalkyl), C 1-C6 alkoxy or- (C 1-C6 alkylene) - (C 1-C6 alkoxy);
R 2 is amino, CN or-NH-C (O) -CH 3;
R 3 is a 5-6 membered heterocycloalkyl or 5-10 membered heteroaryl, optionally substituted with one or more R 3-1; the heteroatoms of the heterocycloalkyl and heteroaryl groups are selected from one or more of N, O, S; the number of the hetero atoms is 1, 2 or 3;
each R 3-1 is independently hydroxy, oxo, C 1-C6 alkyl, -NH (C 1-C6 alkyl), or-S (=o) (=nr 3-1-1)-R3-1-1;
Each R 3-1-1 is independently C 1-C6 alkyl;
Scheme II:
the heterocyclic compound shown in the formula I is a heterocyclic compound shown in the formula I-8,
Wherein ring a is C 3-C7 cycloalkyl;
Each R a is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
m is 0,1 or 2;
R 1 is C 1-C4 alkyl, C 3-C6 cycloalkyl, - (C 1-C4 alkylene) - (C 3-C6 cycloalkyl) or- (C 1-C4 alkylene) - (C 1-C4 alkoxy);
R 3 is a 5-6 membered heteroaryl optionally substituted with one or more R 3-1, or is an 8-10 membered bicyclic heteroaryl optionally substituted with one or more R 3-1; the heteroatoms of the heteroaryl group are selected from one or more of N, O, S; the number of the hetero atoms is 1,2 or 3;
Each R 3-1 is independently oxo, C 1-C6 alkyl, -NH (C 1-C6 alkyl), or-S (=o) (=nr 3-1-1)-R3-1-1;
Each R 3-1-1 is independently C 1-C6 alkyl;
scheme III:
the heterocyclic compound shown in the formula I is a heterocyclic compound shown in the formula I-9,
Wherein, the ring A is cyclopentyl, cyclohexyl, bicyclo [3.1.0] hexyl or spiro [2.4] heptane;
Each R a is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;
m is 0,1 or 2;
R 1 is C 1-C4 alkyl, C 3-C6 cycloalkyl, - (C 1-C4 alkylene) - (C 3-C6 cycloalkyl) or- (C 1-C4 alkylene) - (C 1-C4 alkoxy);
R 3 is a 5-6 membered heteroaryl optionally substituted with one or more R 3-1, or is an 8-10 membered bicyclic heteroaryl optionally substituted with one or more R 3-1; the hetero atom of the 5-6 membered heteroaryl is N, and the number of the hetero atom is 1 or 2; the hetero atom of the 8-10 membered bicyclic heteroaryl is N, and the number of the hetero atom is 1,2 or 3;
Each R 3-1 is independently oxo or C 1-C6 alkyl.
21. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to any one of claims 1 to 20, wherein the heterocyclic compound of formula I has the structure:
Wherein R 1、R3、Ra, m have the definition as defined in any one of claims 1 to 20.
22. The heterocyclic compound of formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof according to claim 1, wherein the heterocyclic compound is selected from any one of the following:
23. A compound of the formula (II),
Wherein R a、R1、R3, n, and m are as defined in claim 22;
for example:
24. A pharmaceutical composition, the pharmaceutical composition comprising: a heterocyclic compound of formula I as described in any one of claims 1-22, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof; and a pharmaceutically acceptable carrier.
25. Use of a substance, characterized in that the substance is a heterocyclic compound of formula I according to any one of claims 1-22, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, a prodrug thereof or a pharmaceutical composition according to claim 24;
The application is to prepare a 15-PGDH inhibitor or prepare a medicament for preventing and/or treating diseases related to 15-PGDH.
26. The use according to claim 25, wherein the 15-PGDH-associated disease is one, two or more of a fibrotic disease, an inflammatory disease, a cardiovascular disease, a wound, an autoimmune disease, a graft versus host disease, hair growth, osteoporosis, an ear disease, an eye disease, neutropenia, diabetes, bladder hypoactivity, promotion of an implant in a stem cell or bone marrow transplant or organ transplant, neurogenesis and neuronal cell death, blood cell remodeling, tissue damage, cervical disease or kidney disease, preferably one or more of fibrosis, inflammatory disease or tissue damage.
27. Use according to claim 26, wherein the fibrotic disease is one or more of pulmonary fibrosis, liver fibrosis, kidney fibrosis, myocardial fibrosis, scleroderma or myelofibrosis, preferably pulmonary fibrosis and/or liver fibrosis, such as pulmonary fibrosis;
The lung fibrosis is preferably idiopathic pulmonary fibrosis;
And/or the inflammatory disease is one or more of chronic obstructive pulmonary disease, acute lung injury, sepsis, exacerbation of asthma and pulmonary disease, inflammatory bowel disease, peptic ulcer, autoinflammatory disease, vasculitis syndrome, acute liver injury, acute kidney injury, non-alcoholic fatty liver, atopic dermatitis, psoriasis, interstitial cystitis or prostatitis syndrome, preferably inflammatory bowel disease;
The inflammatory bowel disease is preferably ulcerative colitis and/or Crohn's disease;
The peptic ulcer is preferably an NSAID-induced ulcer;
the autoinflammatory disease is preferably behcet's disease;
the prostatitis syndromes are preferably chronic prostatitis and/or chronic pelvic pain syndromes;
And/or the cardiovascular disease is one or more of pulmonary arterial hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease, cerebral apoplexy or peripheral circulatory disturbance;
And/or the wound is one or more of a diabetic ulcer, a burn, a pressure ulcer, an acute mucosal injury, including sjogren's syndrome, a mucosal injury, an anti-cancer chemotherapeutic agent related injury, an antimetabolite, a cellular or humoral immunotherapy, or a radiation related injury;
the anticancer chemotherapeutic agent is preferably one or more of an alkylating agent, a DNA synthesis inhibitor or a DNA gyrase inhibitor;
and/or, the autoimmune disease is multiple sclerosis and/or rheumatoid arthritis;
and/or the ear disease is one or more of hearing loss, tinnitus, dizziness or imbalance;
and/or, the eye disease is glaucoma and/or dry eye;
and/or, the neurogenesis and neuronal cell death is one or more of a psychotic neurological disorder, a neuropathy, a neurotoxic disorder, neuropathic pain, or a neurodegenerative disorder;
and/or, the tissue injury is liver injury and/or muscle injury;
The muscle injury is preferably muscle atrophy and/or muscular dystrophy;
And/or, the kidney disease is chronic kidney disease and/or renal failure.
28. Use according to claim 25, wherein the prevention and/or treatment of a disease associated with 15-PGDH is liver regeneration.
29. Use of a heterocyclic compound of formula I as described in any one of claims 1-22, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, a prodrug thereof or a pharmaceutical composition as described in claim 24 for the preparation of a medicament for the prophylaxis and/or treatment of the following diseases; the disease is one or more of fibrosis disease, inflammatory disease or tissue injury;
Preferably, the fibrotic disease, the inflammatory disease and the tissue damage are as claimed in claim 27.
CN202311513322.1A 2022-11-14 2023-11-14 15-PGDH inhibitors Pending CN118027058A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2022114199903 2022-11-14
CN202211419990 2022-11-14
CN202311467246 2023-11-03
CN2023114672465 2023-11-03

Publications (1)

Publication Number Publication Date
CN118027058A true CN118027058A (en) 2024-05-14

Family

ID=90999369

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311513322.1A Pending CN118027058A (en) 2022-11-14 2023-11-14 15-PGDH inhibitors

Country Status (2)

Country Link
CN (1) CN118027058A (en)
WO (1) WO2024104322A1 (en)

Also Published As

Publication number Publication date
WO2024104322A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
JP6704421B2 (en) DNA alkylating agent
KR101081446B1 (en) 2- -57--37-[23-]-4- 2-SUBSTITUTED PHENYL-57-DIALKYL-37-DIHYDROPYRROLE[23-d]PYRIMIDIN-4-ONE DERIVATIVES THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF
CZ20003981A3 (en) Imidazopyridine derivatives inhibiting secretion of stomach acid
JP2004517860A (en) Aza- and polyaza-naphthalenylcarboxamides useful as HIV integrase inhibitors
UA43841C2 (en) IMIDAZOPYRIDINES AND PHARMACEUTICAL COMPOSITION BASED ON THEM
JP2004510819A (en) Aza- and polyaza-naphthalenylcarboxamides useful as HIV integrase inhibitors
WO2023036285A1 (en) Heteroaromatic compound and application thereof
KR20160006207A (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
SK45096A3 (en) Alkoxy alkyl carbamates from imidazo (1,2-a)pyridines, preparation method thereof, pharmaceutical composition containing them and their use
JP7201800B2 (en) 3,9-diazaspiro[5,5]undecane-based compounds as inhibitors of FLT3 and AXL
RU2162470C2 (en) 2,7-substituted derivatives of octahydropyrrolo[1,2-a]pyrazine, method of treatment, pharmaceutical composition, and intermediates
WO2014055938A1 (en) Novel compounds, their preparation and their uses
JP2020147594A (en) Novel dihydropyranopyrimidinone derivatives, and use thereof
CN118027058A (en) 15-PGDH inhibitors
WO2019042443A1 (en) Compound having tyrosine protein kinase jak3-degradation activity
CN111606890A (en) Acryloyl group-containing nuclear transport modulators and uses thereof
WO2019042442A1 (en) Compound having tyrosine protein kinase jak1- or jak2-inhibittion and degradation activity
US20050009809A1 (en) Acridine derivatives and their use as medicaments
CN118027057A (en) Compounds for inhibiting 15-PGDH and use thereof
KR20200065056A (en) Tryptolide derivatives and methods for their preparation and application
US7211588B2 (en) N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US6818642B2 (en) Benzylaminopyrimidines
CN116135856A (en) 15-PGDH inhibitor and application thereof
KR102439021B1 (en) Muti-substituted imidazolo[4,5-c][1,2]thiazine derivatives and use thereof
CN116120285A (en) Heterocyclic compound, preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication